Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Blood

Retrieve available abstracts of 837 articles:
HTML format

Single Articles

    July 2021
  1. JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
    PubMed     Abstract available

  2. BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
    BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
    Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
    PubMed     Abstract available

    CLL-IPI: valid in the era of oral inhibitors?
    Blood. 2021;138:106-107.

    The essential reading list for AML: the m6A transcripts.
    Blood. 2021;138:6-7.

    June 2021
  5. MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
    The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
    Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
    PubMed     Abstract available

  6. KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
    Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
    Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
    PubMed     Abstract available

  7. RUBNITZ JE, Kaspers GJL
    How I treat pediatric acute myeloid leukemia.
    Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
    PubMed     Abstract available

  8. LV K, Ren JG, Han X, Gui J, et al
    Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
    Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
    PubMed     Abstract available

  9. MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
    MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
    Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
    PubMed     Abstract available

  10. CHANG Y, Min J, Jarusiewicz J, Actis M, et al
    Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
    PubMed     Abstract available

    Vaccination against COVID-19: a challenge in CLL.
    Blood. 2021;137:3153-3154.

  12. BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
    MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
    Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
    PubMed     Abstract available

  13. JONES RJ, DeBaun MR
    Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
    Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
    PubMed     Abstract available

  14. TANAKA T, Morita K, Wang F, Loghavi S, et al
    Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
    PubMed     Abstract available

  15. DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
    Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
    Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
    PubMed     Abstract available

  16. AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
    Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
    Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
    PubMed     Abstract available

  17. STEVENSON FK, Forconi F, Kipps TJ
    Exploring the Pathways to Chronic Lymphocytic Leukemia.
    Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
    PubMed     Abstract available

    May 2021
  18. BORELLA G, Da Ros A, Borile G, Porcu E, et al
    Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
    Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
    PubMed     Abstract available

  19. VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
    Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
    Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
    PubMed     Abstract available

  20. ESCRIBANO SERRAT S, Calo Perez A
    Pure erythroid leukemia.
    Blood. 2021;137:2709.

  21. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available

  22. WIMMER J, Hurstel R
    Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
    Blood. 2021;137:2564.

    April 2021
  23. SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
    Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
    Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
    PubMed     Abstract available

  24. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.

  25. DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
    A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
    Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
    PubMed     Abstract available

  26. MITTELMAN SD, Kim J, Raca G, Li G, et al
    Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
    Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.

  27. LEW TE, Tam CS, Seymour JF
    How I treat chronic lymphocytic leukemia after venetoclax.
    Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
    PubMed     Abstract available

  28. DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
    14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
    Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
    PubMed     Abstract available

  29. HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
    Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
    Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
    PubMed     Abstract available

  30. AMES E, Silva O
    Polytypic T-cell prolymphocytic leukemia.
    Blood. 2021;137:2125.

  31. SANDBERG Y, Weerkamp F
    Charcot-Leyden crystals in chronic eosinophilic leukemia.
    Blood. 2021;137:1985.

  32. SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
    KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
    Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
    PubMed     Abstract available

    March 2021
  33. BYRD JC, Woyach JA, Furman RR, Martin P, et al
    Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia.
    Blood. 2021 Mar 30. pii: 475651. doi: 10.1182/blood.2020009617.
    PubMed     Abstract available

  34. NIU X, Rothe K, Chen M, Grasedieck S, et al
    Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia.
    Blood. 2021 Mar 30. pii: 475648. doi: 10.1182/blood.2020007651.
    PubMed     Abstract available

  35. OLSON TL, Cheon H, Xing JC, Olson KC, et al
    Frequent Somatic TET2 Mutations in Chronic NK-LGL Leukemia with Distinct Patterns of Cytopenias.
    Blood. 2021 Mar 30. pii: 475646. doi: 10.1182/blood.2020005831.
    PubMed     Abstract available

  36. SEDA V, Vojackova E, Ondrisova L, Kostalova L, et al
    FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia.
    Blood. 2021 Mar 30. pii: 475649. doi: 10.1182/blood.2020008101.
    PubMed     Abstract available

  37. ZHANG JP, Cheng T
    Modeling acute erythroid leukemia via CRISPR.
    Blood. 2021;137:1565-1567.

  38. CHANG H, Eladl E
    Multiple Auer rods in a mixed-phenotype acute leukemia.
    Blood. 2021;137:1702.

  39. JABBOUR E, Kantarjian H
    A new era in the treatment of acute lymphoblastic leukemia.
    Blood. 2021;137:1563-1564.

  40. FENG M, Xie X, Han G, Zhang T, et al
    YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner.
    Blood. 2021 Mar 24. pii: 475592. doi: 10.1182/blood.2020009676.
    PubMed     Abstract available

  41. ROGERS KA, Andritsos LA, Wei L, McLaughlin E, et al
    Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia.
    Blood. 2021 Mar 22. pii: 475585. doi: 10.1182/blood.2020009688.
    PubMed     Abstract available

  42. RASLAN O, Hsia CC
    Cabot rings in acute myeloid leukemia.
    Blood. 2021;137:1560.

  43. TCHENG M, Roma A, Ahmed N, Smith RW, et al
    Very long chain fatty acid metabolism is required in acute myeloid leukemia.
    Blood. 2021 Mar 15. pii: 475526. doi: 10.1182/blood.2020008551.
    PubMed     Abstract available

  44. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity.
    Blood. 2021 Mar 15. pii: 475523. doi: 10.1182/blood.2020008221.
    PubMed     Abstract available

  45. MURALI I, Kasar S, Naeem A, Tyekucheva S, et al
    Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll).
    Blood. 2021 Mar 8. pii: 475459. doi: 10.1182/blood.2020006765.
    PubMed     Abstract available

  46. TANG J, Yu J, Cai J, Zhang L, et al
    Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation.
    Blood. 2021 Mar 8. pii: 475463. doi: 10.1182/blood.2020010438.
    PubMed     Abstract available

  47. NAZHA A
    Should I rock the boat? When to stop TKIs in CML.
    Blood. 2021;137:1136-1137.

    February 2021
    CAR-T treatment of pediatric AML: a long and winding road.
    Blood. 2021;137:1004-1006.

  49. MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
    A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood. 2021;137:1019-1023.
    PubMed     Abstract available

  50. WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
    CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Blood. 2021;137:1037-1049.
    PubMed     Abstract available

  51. HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
    Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
    Blood. 2021;137:1050-1060.
    PubMed     Abstract available

  52. CHEN J, Sathiaseelan V, Moore AD, Tan S, et al
    ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
    Blood. 2021 Feb 22. pii: 475287. doi: 10.1182/blood.2020009960.
    PubMed     Abstract available

  53. Pediatric disease risk index for acute leukemia.
    Blood. 2021;137:1001.

  54. QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
    A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
    Blood. 2021;137:983-993.
    PubMed     Abstract available

  55. SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
    UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
    Blood. 2021;137:908-922.
    PubMed     Abstract available

  56. LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
    Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Blood. 2021;137:939-944.
    PubMed     Abstract available

  57. SCHMALBROCK LK, Dolnik A, Cocciardi S, Strang E, et al
    Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Blood. 2021 Feb 17. pii: 475246. doi: 10.1182/blood.2020007626.
    PubMed     Abstract available

  58. HERBAUX C, Kornauth C, Poulain S, Chong SJF, et al
    BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.
    Blood. 2021 Feb 17. pii: 475244. doi: 10.1182/blood.2020007303.
    PubMed     Abstract available

  59. GILL S
    DARTs point the way forward in AML.
    Blood. 2021;137:720-721.

  60. NG AP
    Unraveling a T-ALL Tapestri.
    Blood. 2021;137:726-727.

  61. HERGOTT CB, Pozdnyakova O
    Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
    Blood. 2021;137:860.

  62. RAASTAD K, Huang Q
    Burkitt leukemia with immature B-cell phenotype mimicking acute lymphoblastic leukemia.
    Blood. 2021;137:718.

  63. GRANT S
    Targeting cereblon in AML.
    Blood. 2021;137:584-586.

  64. BROWN JR
    AKT: a key to RT?
    Blood. 2021;137:582-584.

  65. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available

  66. FALINI B, Brunetti L, Martelli MP
    How I diagnose and treat NPM1-mutated AML.
    Blood. 2021;137:589-599.
    PubMed     Abstract available

    January 2021
  67. GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
    Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.
    Blood. 2021;137:569-572.

  68. RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
    Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.
    Blood. 2021;137:500-512.
    PubMed     Abstract available

  69. SHOUVAL R, Soiffer RJ
    Primum non nocere: allo-HSCT for AML in CR1.
    Blood. 2021;137:438-439.

  70. COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
    High frequency of clonal hematopoiesis in Erdheim-Chester disease.
    Blood. 2021;137:485-492.
    PubMed     Abstract available

  71. ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
    Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
    Blood. 2021;137:471-484.
    PubMed     Abstract available

  72. SONG Q, Wang X, Wu X, Qin H, et al
    Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Blood. 2021 Jan 27. pii: 475053. doi: 10.1182/blood.2020006345.
    PubMed     Abstract available

  73. RIO-MACHIN A, Fitzgibbon J
    Germline ETV6 variants: not ALL created equally.
    Blood. 2021;137:288-289.

  74. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available

  75. WEN Z, Yun G, Hebert A, Kong G, et al
    NrasQ61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
    Blood. 2021 Jan 19. pii: 475000. doi: 10.1182/blood.2020009082.
    PubMed     Abstract available

  76. SHADMAN M, Ujjani C
    Vaccinations in CLL: implications for COVID-19.
    Blood. 2021;137:144-146.

  77. MERTENS D, Kronke J
    Triggering T-cell activity in CLL.
    Blood. 2021;137:150-151.

  78. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.

  79. AL MOOSAWI M, Vercauteren S
    Cerebrospinal fluid with unusual natural killer cell population.
    Blood. 2021;137:281.

  80. IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
    Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
    Blood. 2021;137:216-231.
    PubMed     Abstract available

  81. SALIB C, Hussein S
    A case of hairy cell leukemia with markedly hypocellular marrow mimicking aplastic anemia.
    Blood. 2021;137:142.

  82. SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
    Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction.
    Blood. 2021;137:20-28.
    PubMed     Abstract available

  83. KENNEDY E, Coulter EM, Halliwell E, Profitos-Peleja N, et al
    TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.
    Blood. 2021 Jan 7. pii: 474915. doi: 10.1182/blood.2020005964.
    PubMed     Abstract available

  84. CORRE J
    Undetectable MRD can change the deal.
    Blood. 2021;137:5-6.

    Superenhancing AML with Trib1.
    Blood. 2021;137:8-9.

    December 2020
  86. MATTERN S, Nann D
    Small lymphocytic leukemia with herpes simplex virus infection simulating metastatic cancer.
    Blood. 2020;136:3087.

  87. KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
    Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
    Blood. 2020;136:3041-3050.
    PubMed     Abstract available

  88. FURSTENAU M, Fink AM, Schilhabel A, Weiss J, et al
    B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide.
    Blood. 2020 Dec 23. pii: 474779. doi: 10.1182/blood.2020008609.
    PubMed     Abstract available

  89. FAZIO G, Bardini M, de Lorenzo P, Grioni A, et al
    Blood. 2020 Dec 22. pii: 474771. doi: 10.1182/blood.2020009032.

  90. SLAGER SL, Lanasa MC, Marti GE, Achenbach SJ, et al
    Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families.
    Blood. 2020 Dec 21. pii: 474760. doi: 10.1182/blood.2020006322.
    PubMed     Abstract available

  91. TARDIVON D, Antoszewski M, Zangger N, Nkosi M, et al
    Notch Signaling Promotes Disease Initiation and Progression in Murine Chronic Lymphocytic Leukemia.
    Blood. 2020 Dec 18. pii: 474750. doi: 10.1182/blood.2020006701.
    PubMed     Abstract available

  92. MIAO H, Kim E, Chen D, Purohit T, et al
    Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
    Blood. 2020;136:2958-2963.

  93. LIU Y, Panetta JC, Yang W, Karol SE, et al
    Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
    Blood. 2020;136:2955-2958.

  94. HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
    Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Blood. 2020;136:2918-2926.
    PubMed     Abstract available

  95. BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
    MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.
    Blood. 2020;136:2764-2773.
    PubMed     Abstract available

  96. PLATZBECKER U, Kordasti S
    Natural born survivors: the inglorious TP53.
    Blood. 2020;136:2727-2728.

  97. OBERBECK S, Schrader A, Warner K, Jungherz D, et al
    Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
    Blood. 2020;136:2786-2802.
    PubMed     Abstract available

  98. SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
    TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Blood. 2020;136:2812-2823.
    PubMed     Abstract available

  99. STAUBER J, Greally J, Steidl U
    Preleukemic and Leukemic Evolution at the Stem Cell Level.
    Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
    PubMed     Abstract available

  100. TASHAKORI M, Khoury JD
    B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma.
    Blood. 2020;136:2720.

  101. LULLA P, Naik S, Vasileiou S, Tzannou I, et al
    Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.
    Blood. 2020 Dec 3. pii: 474389. doi: 10.1182/blood.2020009471.
    PubMed     Abstract available

  102. PLEYER C, Ali MA, Cohen JI, Tian X, et al
    Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
    Blood. 2020 Dec 1. pii: 474376. doi: 10.1182/blood.2020008758.
    PubMed     Abstract available

    November 2020
  103. CORTES J
    How to manage CML patients with comorbidities.
    Blood. 2020;136:2507-2512.
    PubMed     Abstract available

  104. NADEU F, Royo R, Clot G, Duran-Ferrer M, et al
    IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
    Blood. 2020 Nov 19. pii: 474211. doi: 10.1182/blood.2020008311.
    PubMed     Abstract available

  105. RAO S
    RUNX1 and inv(16) are frenemies in AML.
    Blood. 2020;136:2361-2362.

  106. PERL AE
    MLL-menin and FLT3 inhibitors team up for AML.
    Blood. 2020;136:2369-2370.

  107. DZAMA MM, Steiner M, Rausch J, Sasca D, et al
    Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Blood. 2020;136:2442-2456.
    PubMed     Abstract available

  108. KLINTMAN J, Appleby N, Stamatopoulos B, Ridout K, et al
    Genomic and transcriptomic correlates of Richter's transformation in Chronic Lymphocytic Leukemia.
    Blood. 2020 Nov 18. pii: 474199. doi: 10.1182/blood.2020005650.
    PubMed     Abstract available

  109. SURKA C, Jin L, Mbong N, Lu CC, et al
    CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells.
    Blood. 2020 Nov 16. pii: 474181. doi: 10.1182/blood.2020008676.
    PubMed     Abstract available

  110. WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
    Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
    Blood. 2020;136:2319-2333.
    PubMed     Abstract available

  111. SHARMA S, Pavlasova G, Seda V, Cerna K, et al
    miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors.
    Blood. 2020 Nov 10. pii: 474127. doi: 10.1182/blood.2020005627.
    PubMed     Abstract available

  112. CHEVILLON F, Clappier E, Arfeuille C, Cayuela JM, et al
    Minimal Residual Disease Quantification in Ovarian Tissue Collected in Patients in Complete Remission of Acute Leukemia.
    Blood. 2020 Nov 10. pii: 474130. doi: 10.1182/blood.2020007782.
    PubMed     Abstract available

  113. RIBERA JM, Morgades M, Ciudad J, Montesinos P, et al
    Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia.
    Blood. 2020 Nov 4. pii: 474081. doi: 10.1182/blood.2020007311.
    PubMed     Abstract available

  114. GOTTSCHALK HOJFELDT S, Grell K, Abrahamsson J, Lund B, et al
    Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia.
    Blood. 2020 Nov 4. pii: 474076. doi: 10.1182/blood.2020006583.
    PubMed     Abstract available

    October 2020
  115. ROY A
    A "gut feeling" about precursor B-ALL.
    Blood. 2020;136:1995-1996.

  116. YANG W, Devidas M, Liu Y, Smith C, et al
    Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations.
    Blood. 2020 Oct 26. pii: 469753. doi: 10.1182/blood.2020008471.

    Rerouting DOT1L inhibitors in leukemia.
    Blood. 2020;136:1900-1901.

    Cost-effectiveness targeting CLL.
    Blood. 2020;136:1896-1898.

  119. PERNER F, Gadrey JY, Xiong Y, Hatton C, et al
    Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.
    Blood. 2020;136:1983-1988.

  120. COOK LB, Phillips AA
    How I treat Adult T-cell leukemia/lymphoma.
    Blood. 2020 Oct 19. pii: 469694. doi: 10.1182/blood.2019004045.
    PubMed     Abstract available

  121. BRIVIO E, Locatelli F, Lopez-Yurda M, Malone A, et al
    A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
    Blood. 2020 Oct 16. pii: 469618. doi: 10.1182/blood.2020007848.
    PubMed     Abstract available

  122. PASSARO D
    Myeloid cells hold the master key for T-ALL spread.
    Blood. 2020;136:1799-1800.

  123. INABA H, Pui CH
    Intensive but tender care for infant ALL.
    Blood. 2020;136:1797-1798.

  124. DUPLOYEZ N, Jamrog LA, Fregona V, Hamelle C, et al
    Germline PAX5 mutation predisposes to familial B acute lymphoblastic leukemia.
    Blood. 2020 Oct 9. pii: 464429. doi: 10.1182/blood.2020005756.
    PubMed     Abstract available

  125. SIDHOM I, Shaaban K, Youssef SH, Ali N, et al
    Reduced-intensity therapy of pediatric lymphoblastic leukemia: Impact of residual disease early in remission induction.
    Blood. 2020 Oct 8. pii: 464272. doi: 10.1182/blood.2020007977.
    PubMed     Abstract available

  126. GODWIN CD, Zhou Y, Othus M, Asmuth MM, et al
    Acute Myeloid Leukemia Measurable Residual Disease Detection by Flow Cytometry in Peripheral Blood Versus Bone Marrow.
    Blood. 2020 Oct 7. pii: 464167. doi: 10.1182/blood.2020006219.

  127. NIEMANN CU, Levin MD, Dubois J, Kersting S, et al
    Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2020 Oct 7. pii: 464169. doi: 10.1182/blood.2020008608.

  128. BARKSDALE B, Leith CP
    CD138+ carcinocythemia mimicking plasma cell leukemia by flow cytometry.
    Blood. 2020;136:1698.

    HHEX expression drives AML development.
    Blood. 2020;136:1575-1576.

  130. TAKEDA R, Asada S, Park SJ, Yokoyama A, et al
    HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Blood. 2020;136:1670-1684.
    PubMed     Abstract available

    September 2020
  131. WANG W, Thakral B
    CD123+CD4+CD56+ neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia?
    Blood. 2020;136:1565.

  132. THANGAVELU G, Wang C, Loschi M, Saha A, et al
    Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses.
    Blood. 2020 Sep 24. pii: 463979. doi: 10.1182/blood.2020005628.
    PubMed     Abstract available

  133. TAYLOR J, Mi X, North K, Binder M, et al
    Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.
    Blood. 2020;136:1477-1486.
    PubMed     Abstract available

  134. PEPPER M, Tan B
    Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia.
    Blood. 2020;136:1467.

  135. Enshaei A, O'Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135(17):1438-1446.
    Blood. 2020;136:1468.

  136. PINA-OVIEDO S, Thanendrarajan S
    Meningeosis myelomatosis.
    Blood. 2020;136:1466.

  137. STENGER D, Stief TA, Kaeuferle T, Willier S, et al
    Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
    Blood. 2020;136:1407-1418.
    PubMed     Abstract available

  138. UY GL, Aldoss I, Foster MC, Sayre PH, et al
    Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.
    Blood. 2020 Sep 14. pii: 463757. doi: 10.1182/blood.2020007732.
    PubMed     Abstract available

  139. ZHEN T, Cao Y, Ren G, Zhao L, et al
    RUNX1 and CBFbeta-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Blood. 2020 Sep 14. pii: 463758. doi: 10.1182/blood.2020007747.
    PubMed     Abstract available

  140. VICENTE DUENAS C, Janssen S, Oldenburg M, Auer F, et al
    An intact gut microbiome protects genetically predisposed mice against leukemia.
    Blood. 2020 Sep 10. pii: 463729. doi: 10.1182/blood.2019004381.
    PubMed     Abstract available

  141. KAWABATA KC, Zong H, Meydan C, Wyman S, et al
    BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
    Blood. 2020 Sep 10. pii: 463728. doi: 10.1182/blood.2019001745.
    PubMed     Abstract available

  142. WILL B
    No keto for AML stem cells!
    Blood. 2020;136:1219-1221.

    Detonating T-ALL.
    Blood. 2020;136:1218-1219.

  144. YUSUF RZ, Saez B, Sharda A, van Gastel N, et al
    Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
    Blood. 2020;136:1303-1316.
    PubMed     Abstract available

  145. SONG L, Yu B, Yang Y, Liang J, et al
    Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.
    Blood. 2020 Sep 8. pii: 463712. doi: 10.1182/blood.2020005622.
    PubMed     Abstract available

    When CLL meets COVID-19.
    Blood. 2020;136:1115-1116.

  147. MATO AR, Roeker LE, Lamanna N, Allan JN, et al
    Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
    Blood. 2020;136:1134-1143.
    PubMed     Abstract available

  148. FULTANG L, Booth S, Yogev O, Martins da Costa B, et al
    Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.
    Blood. 2020;136:1155-1160.
    PubMed     Abstract available

  149. TEACHEY DT, Hunger SP, Loh ML
    Optimizing Therapy in the Modern Age: Differences in Length of Maintenance Therapy in Acute Lymphoblastic Leukemia.
    Blood. 2020 Sep 2. pii: 463610. doi: 10.1182/blood.2020007702.
    PubMed     Abstract available

  150. SHANMUGANATHAN N, Pagani IS, Ross DM, Park S, et al
    Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
    Blood. 2020 Sep 1. pii: 463598. doi: 10.1182/blood.2020005514.
    PubMed     Abstract available

  151. XIAO W, Chan A, Waarts MR, Mishra T, et al
    Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 mutated acute myeloid leukemia.
    Blood. 2020 Sep 1. pii: 463602. doi: 10.1182/blood.2020007897.
    PubMed     Abstract available

  152. FENWARTH L, Thomas X, de Botton S, Duployez N, et al
    A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.
    Blood. 2020 Sep 1. pii: 463599. doi: 10.1182/blood.2020005524.
    PubMed     Abstract available

    August 2020
  153. TAN Y, Wang X, Song H, Zhang Y, et al
    A PML/RARalpha direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.
    Blood. 2020 Aug 27. pii: 463523. doi: 10.1182/blood.2020005698.
    PubMed     Abstract available

  154. WANG HY, Tzachanis D
    Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.
    Blood. 2020;136:1112.

  155. LUEDKE C, Rein L
    Transformation to erythroblastic sarcoma from myeloid neoplasm with PCM1-JAK2.
    Blood. 2020;136:1113.

  156. DEWOLF S, Tallman MS
    How I treat relapsed or refractory AML.
    Blood. 2020;136:1023-1032.
    PubMed     Abstract available

  157. FANG H, Xu J
    Blastoid plasma cell leukemia mimicking acute leukemia.
    Blood. 2020;136:1012.

  158. LIU H
    NUP98 rearrangement in B lymphoblastic leukemia with hyperdiploidy.
    Blood. 2020;136:1011.

  159. MALINGE S
    SNAIL trail in myeloid malignancies.
    Blood. 2020;136:920-921.

    Deletions in BCP-ALL result in a TAD more FLT3.
    Blood. 2020;136:919-920.

  161. CARMICHAEL CL, Wang J, Nguyen T, Kolawole O, et al
    The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1.
    Blood. 2020;136:957-973.
    PubMed     Abstract available

  162. ALBERTI-SERVERA L, Demeyer S, Govaerts I, Swings T, et al
    Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
    Blood. 2020 Aug 18. pii: 463329. doi: 10.1182/blood.2020006996.
    PubMed     Abstract available

  163. JOLLY CJ, Pimanda JE
    Titans awake: HMAs for virus-driven ATL.
    Blood. 2020;136:777-779.

  164. WATANABE T, Yamashita S, Ureshino H, Kamachi K, et al
    Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
    Blood. 2020;136:871-884.
    PubMed     Abstract available

    Erythroleukemia: all roads lead to GATA1?
    Blood. 2020;136:648-649.

  166. FAGNAN A, Bagger FO, Pique-Borras MR, Ignacimouttou C, et al
    Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
    Blood. 2020;136:698-714.
    PubMed     Abstract available

  167. GARCIA-MANERO G, Griffiths EA, Steensma DP, Roboz GJ, et al
    Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
    Blood. 2020;136:674-683.
    PubMed     Abstract available

  168. RODERICK JE, Gallagher KM, Murphy LC, O'Connor KW, et al
    Prostaglandin E2 stimulates cAMP signaling and re-sensitizes human leukemia cells to glucocorticoid-induced cell death.
    Blood. 2020 Aug 5. pii: 461709. doi: 10.1182/blood.2020005712.
    PubMed     Abstract available

    July 2020
  169. YOSHINO S, Yokoyama T, Sunami Y, Takahara T, et al
    Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
    Blood. 2020 Jul 30. pii: 461620. doi: 10.1182/blood.2019004586.
    PubMed     Abstract available

  170. CARROLL M
    A common protein target for an uncommon subtype of AML.
    Blood. 2020;136:377-378.

  171. BEAUMONT AL, Suner L
    Drug-induced aseptic meningitis in a Ph+ ALL patient with meningeal involvement.
    Blood. 2020;136:520.

  172. ASSAF N, Terre C
    Double translocation or gene insertion? A BCR/ABL1 fusion in Philadelphia-negative CML.
    Blood. 2020;136:521.

  173. SAAD M, Loh KP, Tooze JA, Pardee TS, et al
    Geriatric assessment and survival among older adults receiving post-remission therapy for acute myeloid leukemia.
    Blood. 2020 Jul 22. pii: 461543. doi: 10.1182/blood.2020005498.

  174. NISHII R, Baskin-Doerfler R, Yang W, Oak N, et al
    Molecular Basis of ETV6-Mediated Predisposition to Childhood Acute Lymphoblastic Leukemia.
    Blood. 2020 Jul 21. pii: 461432. doi: 10.1182/blood.2020006164.
    PubMed     Abstract available

  175. BRADY SW, Ma X, Zhou BS, Pui CH, et al
    Response to "Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?"
    Blood. 2020 Jul 20. pii: 461427. doi: 10.1182/blood.2020008107.

  176. BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
    Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
    Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
    PubMed     Abstract available

  177. PIVA E, Tosato F
    Promyelocytic leukemia with basophil-like granules.
    Blood. 2020;136:372.

  178. STOCK W
    Thrombosis in ALL: a risk without clear mitigation.
    Blood. 2020;136:264-265.

  179. MOLINA O, Vinyoles M, Granada I, Roca-Ho H, et al
    Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL.
    Blood. 2020;136:313-327.
    PubMed     Abstract available

  180. MUJAHED H, Miliara S, Neddermeyer A, Bengtzen S, et al
    AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.
    Blood. 2020;136:339-352.
    PubMed     Abstract available

  181. TSURUTA Y, Karube K
    Hodgkin and Reed-Sternberg-like cells infected with human T-cell leukemia virus type 1.
    Blood. 2020;136:257.

  182. Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017;129(24):3165-3174.
    Blood. 2020;136:259.

  183. LYAPICHEV KA, Jelloul FZ
    Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma.
    Blood. 2020;136:258.

  184. TOMIZAWA D, Miyamura T, Imamura T, Watanabe T, et al
    A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial.
    Blood. 2020 Jul 7. pii: 461277. doi: 10.1182/blood.2019004741.
    PubMed     Abstract available

  185. FRIEDRICH C, Barreau S
    A splenic lymphoma/leukemia with a spontaneous blast decrease without treatment.
    Blood. 2020;136:148.

    Occupy BTK: the key to controlling CLL.
    Blood. 2020;136:4-6.

  187. LICHT JD
    Oncogenesis by E2A-PBX1 in ALL: RUNX and more.
    Blood. 2020;136:3-4.

  188. KHAN DH, Mullokandov M, Wu Y, Voisin V, et al
    Mitochondrial carrier homolog 2 is necessary for AML survival.
    Blood. 2020;136:81-92.
    PubMed     Abstract available

  189. SUN C, Nierman P, Kendall EK, Cheung J, et al
    Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
    Blood. 2020;136:93-105.
    PubMed     Abstract available

  190. FALINI B, Brunetti L, Sportoletti P, Martelli MP, et al
    NPM1-mutated acute myeloid leukemia: from bench to bedside.
    Blood. 2020 Jul 1. pii: 461241. doi: 10.1182/blood.2019004226.
    PubMed     Abstract available

    June 2020
  191. GAYNON PS, Orgel E, Ji L
    Pre-existing or Therapy-induced Mutations in Relapsed Acute Lymphoblastic Leukemia?
    Blood. 2020 Jun 30. pii: 461230. doi: 10.1182/blood.2020005258.

  192. BULAEVA E, Pellacani D, Nakamichi N, Hammond CA, et al
    MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus.
    Blood. 2020 Jun 29. pii: 461224. doi: 10.1182/blood.2020006374.
    PubMed     Abstract available

  193. HUNGER SP, Raetz E
    How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population.
    Blood. 2020 Jun 26. pii: 461194. doi: 10.1182/blood.2019004043.
    PubMed     Abstract available

  194. GIOTOPOULOS G, Huntly BJP
    CML: new tools to answer old questions.
    Blood. 2020;135:2327-2328.

  195. STANKOVIC T, Kwok M
    Genetics in the era of targeted CLL therapy.
    Blood. 2020;135:2333-2334.

  196. GEYER HL, Gazelka H, Mesa R
    How I treat pain in hematologic malignancies safely with opioid therapy.
    Blood. 2020;135:2354-2364.
    PubMed     Abstract available

  197. TAUSCH E, Schneider C, Robrecht S, Zhang C, et al
    Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
    Blood. 2020;135:2402-2412.
    PubMed     Abstract available

  198. MATSUMURA T, Nakamura-Ishizu A, Muddineni SSNA, Tan DQ, et al
    Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia.
    Blood. 2020 Jun 23. pii: 461100. doi: 10.1182/blood.2019004292.
    PubMed     Abstract available

  199. CUNEO A, Scarfo L, Reda G, Varettoni M, et al
    Blood. 2020 Jun 19. pii: 461059. doi: 10.1182/blood.2020006854.

  200. RAFFEL S, Klimmeck D, Falcone M, Demir A, et al
    Quantitative proteomics reveals specific metabolic features of Acute Myeloid Leukemia stem cells.
    Blood. 2020 Jun 18. pii: 461031. doi: 10.1182/blood.2019003654.
    PubMed     Abstract available

  201. Setd2 deficiency accelerated MDS-related leukemia.
    Blood. 2020;135:2326.

  202. CRUZ HERNANDEZ D, Metzner M, de Groot AP, Usukhbayar B, et al
    Sensitive, Rapid Diagnostic Test For Transient Abnormal Myelopoiesis and Myeloid Leukemia of Down Syndrome.
    Blood. 2020 Jun 18. pii: 461036. doi: 10.1182/blood.2020005610.

  203. BROWN JR
    Inverting the BTK-BCL2 order.
    Blood. 2020;135:2205-2207.

  204. GRANTS JM, Wegrzyn J, Hui T, O'Neill K, et al
    Altered microRNA expression links IL6 and TNF-induced inflammaging with myeloid malignancy in humans and mice.
    Blood. 2020;135:2235-2251.
    PubMed     Abstract available

  205. LIN VS, Lew TE, Handunnetti SM, Blombery P, et al
    BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Blood. 2020;135:2266-2270.
    PubMed     Abstract available

  206. CHEN BY, Song J, Hu CL, Chen SB, et al
    SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
    Blood. 2020;135:2271-2285.
    PubMed     Abstract available

    ON TRacK towards novel targets in leukemia.
    Blood. 2020;135:2117-2119.

  208. LOWENBERG B, Huls G
    The long road: improving outcome in elderly "unfit" AML?
    Blood. 2020;135:2114-2115.

  209. LUCAS F, Larkin K, Gregory CT, Orwick S, et al
    Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Blood. 2020;135:2192-2195.

  210. WEI AH, Montesinos P, Ivanov V, DiNardo CD, et al
    Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Blood. 2020;135:2137-2145.
    PubMed     Abstract available

  211. DIRAL E, Mori S, Antolini L, Abruzzese E, et al
    Increased tumor burden in Chronic Myeloid Leukemia patients after 36 months of imatinib discontinuation.
    Blood. 2020 Jun 9. pii: 460734. doi: 10.1182/blood.2019004371.

  212. PATEL K, Isufi I, Kothari S, Davidoff AJ, et al
    Cost-Effectiveness of First-Line Ibrutinib versus Third-Line in Patients with Untreated Chronic Lymphocytic Leukemia.
    Blood. 2020 Jun 9. pii: 460741. doi: 10.1182/blood.2020004922.
    PubMed     Abstract available

  213. Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.
    Blood. 2020;135:2111.

  214. RATNER L
    Predicting the future: adult T-cell leukemia.
    Blood. 2020;135:2013-2014.

  215. ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
    Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
    Blood. 2020 Jun 4. pii: 460669. doi: 10.1182/blood.2019004583.
    PubMed     Abstract available

  216. AN J, Ko M
    Decoding ribosomes to keep growing (in AML).
    Blood. 2020;135:2015-2016.

  217. SAINI NY, Marin D, Ledesma C, Delgado R, et al
    Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2020 Jun 3. pii: 460671. doi: 10.1182/blood.2019004685.

  218. TRAN QUANG C, Zaniboni B, Humeau R, Lengline E, et al
    Preclinical Efficacy of Humanized, non-FcgammaR Binding Anti-CD3 Antibodies in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2020 Jun 1. pii: 460600. doi: 10.1182/blood.2019003801.
    PubMed     Abstract available

    May 2020

  219. Passet M, Boissel N, Sigaux F, et al; Group for Research on Adult ALL (GRAALL). PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. Blood. 2019;133(3):280-284.
    Blood. 2020;135:2011.

  220. NEGRETE D, Huang Q
    A striking case of iatrogenic granulocytic nuclear abnormality in the bone marrow.
    Blood. 2020;135:2010.

  221. SCHRATZ KE, Haley L, Danoff SK, Blackford AL, et al
    Cancer spectrum and outcomes in the Mendelian short telomere syndromes.
    Blood. 2020;135:1946-1956.
    PubMed     Abstract available

  222. ABDO C, Thonier F, Simonin M, Kaltenbach S, et al
    Caution encouraged in NGS immunogenetic analyses in Acute Lymphoblastic Leukemia.
    Blood. 2020 May 21. pii: 456040. doi: 10.1182/blood.2020005613.

  223. SUNG PJ, Babushok DV
    Born to RUNX1.
    Blood. 2020;135:1824-1825.

  224. TAM CS, Seymour JF
    A predictive tool for early-stage CLL.
    Blood. 2020;135:1820-1821.

  225. SIMON L, Spinella JF, Yao CY, Lavallee VP, et al
    High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
    Blood. 2020;135:1882-1886.
    PubMed     Abstract available

  226. MENSSEN AJ, Walter MJ
    Genetics of Progression from MDS to Secondary Leukemia.
    Blood. 2020 May 19. pii: 456027. doi: 10.1182/blood.2019000942.
    PubMed     Abstract available

  227. SUN L, Babushok DV
    Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.
    Blood. 2020 May 19. pii: 456026. doi: 10.1182/blood.2019000940.
    PubMed     Abstract available

  228. DUNBAR A, Rampal R, Levine RL
    Secondary leukemia to myeloproliferative neoplasms.
    Blood. 2020 May 19. pii: 456028. doi: 10.1182/blood.2019000943.
    PubMed     Abstract available

  229. SOULIER J
    Introduction to a review series on secondary leukemia.
    Blood. 2020 May 19. pii: 456030. doi: 10.1182/blood.2019004171.

  230. SCOTT HS, Hahn CN, Brown AL
    Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
    Blood. 2020 May 19. pii: 456025. doi: 10.1182/blood.2019000937.
    PubMed     Abstract available

  231. JELINEK T, Zuchnicka J
    Peripheral T-cell lymphoma, NOS, with rapidly progressing leukocytosis mimicking acute lymphoblastic leukemia.
    Blood. 2020;135:1816.

  232. GEBRU MT, Atkinson JM, Young M, Zhang L, et al
    Glucocorticoids enhance the anti-leukemic activity of FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.
    Blood. 2020 May 12. pii: 455305. doi: 10.1182/blood.2019003124.
    PubMed     Abstract available

  233. SONG C, Ge Z, Ding Y, Tan BH, et al
    IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia.
    Blood. 2020 May 12. pii: 455304. doi: 10.1182/blood.2019002655.
    PubMed     Abstract available

  234. TULSTRUP M, Moriyama T, Jiang C, Grosjean M, et al
    Effects of germline variants in DHFR and FPGS on methotrexate metabolism and relapse of leukemia.
    Blood. 2020 May 11. pii: 455060. doi: 10.1182/blood.2020005064.
    PubMed     Abstract available

  235. YANG M, Safavi S, Woodward EL, Duployez N, et al
    13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.
    Blood. 2020 May 8. pii: 454973. doi: 10.1182/blood.2019004684.
    PubMed     Abstract available

  236. KATER AP, Melenhorst JJ
    CAR-T and ibrutinib vs CLL: sequential or simultaneous?
    Blood. 2020;135:1611-1612.

  237. GERBY B, Hoang T
    A targetable cue in T-cell malignancy.
    Blood. 2020;135:1616-1617.

  238. RONNER L, Podoltsev N, Gotlib J, Heaney ML, et al
    Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
    Blood. 2020;135:1696-1703.
    PubMed     Abstract available

  239. GAUTHIER J, Hirayama AV, Purushe J, Hay KA, et al
    Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
    Blood. 2020;135:1650-1660.
    PubMed     Abstract available

    April 2020
  240. DE DOMINICI M, Porazzi P, Xiao Y, Chao A, et al
    Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
    Blood. 2020;135:1560-1573.
    PubMed     Abstract available

  241. SCHMOELLERL J, Barbosa IAM, Eder T, Brandstoetter T, et al
    CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia.
    Blood. 2020 Apr 28. pii: 454667. doi: 10.1182/blood.2019003267.
    PubMed     Abstract available

  242. LONG J, Jia MY, Fang WY, Chen XJ, et al
    FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Blood. 2020;135:1472-1483.
    PubMed     Abstract available

  243. ENSHAEI A, O'Connor D, Bartram J, Hancock J, et al
    A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
    Blood. 2020;135:1438-1446.
    PubMed     Abstract available

  244. KRAUSE DS
    The Fox(o) and the HDAC.
    Blood. 2020;135:1416-1417.

    Go with the flow: simplified MRD in LMIC ALL.
    Blood. 2020;135:1414-1415.

  246. COOK LBM, Rowan AG
    CD28 fusions: an opportunity for young ATL?
    Blood. 2020;135:1415-1416.

  247. LIU H, Hu S
    Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation.
    Blood. 2020;135:1506.

  248. WIERDA WG, Tambaro FP
    How I manage CLL with venetoclax-based treatments.
    Blood. 2020;135:1421-1427.
    PubMed     Abstract available

  249. CLESHAM K, Rao V, Bartram J, Ancliff P, et al
    Blinatumomab for infant acute lymphoblastic leukemia.
    Blood. 2020;135:1501-1504.

  250. YOSHIDA N, Shigemori K, Donaldson N, Trevisani C, et al
    Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.
    Blood. 2020;135:1467-1471.
    PubMed     Abstract available

  251. ORVAIN C, Balsat M, Tavernier E, Marolleau JP, et al
    Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study.
    Blood. 2020 Apr 22. pii: 454452. doi: 10.1182/blood.2020004919.
    PubMed     Abstract available

  252. MARRA A, Martino G
    Placental myeloid sarcoma.
    Blood. 2020;135:1410.

  253. HAROCHE J, Cohen-Aubart F, Amoura Z
    Erdheim-Chester disease.
    Blood. 2020;135:1311-1318.
    PubMed     Abstract available

  254. SCHETELIG J, Baldauf H, Heidenreich F, Massalski C, et al
    External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
    Blood. 2020;135:1386-1395.
    PubMed     Abstract available

  255. PATNAIK MM, Sallman DA, Mangaonkar A, Heuer R, et al
    Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML).
    Blood. 2020 Apr 15. pii: 454390. doi: 10.1182/blood.2019004352.

  256. PI WC, Wang J, Shimada M, Lin JW, et al
    E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.
    Blood. 2020 Apr 10. pii: 454360. doi: 10.1182/blood.2019003312.
    PubMed     Abstract available

  257. HSU A, Freeman N
    The fertile field of "isomopic" immune dysregulation as a nidus for lymphoproliferative disorders.
    Blood. 2020;135:1303.

  258. SAENZ DT, Fiskus W, Mill CP, Perera D, et al
    Mechanistic basis and efficacy of targeting the beta-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
    Blood. 2020;135:1255-1269.
    PubMed     Abstract available

  259. CONDOLUCI A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, et al
    International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.
    Blood. 2020 Apr 8. pii: 454292. doi: 10.1182/blood.2019003453.
    PubMed     Abstract available

  260. LIN H, Rothe K, Chen M, Wu A, et al
    The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML.
    Blood. 2020 Apr 8. pii: 454304. doi: 10.1182/blood.2019003636.
    PubMed     Abstract available

  261. SIMKINS A, Dunleavy K
    Tackling Burkitt when it's back.
    Blood. 2020;135:1078-1080.

  262. GHANNAM JY, Xu X, Maric I, Dillon L, et al
    Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation.
    Blood. 2020;135:1185-1188.

    March 2020
  263. OTTEMA S, Mulet-Lazaro R, Beverloo HB, Erpelinck CAJ, et al
    Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Blood. 2020 Mar 27. pii: 454178. doi: 10.1182/blood.2019003701.
    PubMed     Abstract available

  264. GANG EJ, Kim HN, Hsieh YT, Ruan Y, et al
    Integrin alpha6 mediates drug resistance of acute lymphoblastic B-cell leukemia.
    Blood. 2020 Mar 27. pii: 454180. doi: 10.1182/blood.2019001417.
    PubMed     Abstract available

  265. KLEIN E, Bidet A
    MYC and KMT2A multiple extra copies in acute myeloid leukemia.
    Blood. 2020;135:1070.

  266. JINNOUCHI F, Yamauchi T, Yurino A, Nunomura T, et al
    Establishment of a human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells.
    Blood. 2020 Mar 23. pii: 452764. doi: 10.1182/blood.2019002194.
    PubMed     Abstract available

  267. MATNANI R, Weissmann D
    Hyperdiploid B-lymphoblastic leukemia/lymphoma with hypereosinophilia and very few circulating lymphoblasts.
    Blood. 2020;135:974.

  268. ELITZUR S, Izraeli S
    It takes a village to grow leukemia.
    Blood. 2020;135:886-887.

  269. CHIANG MY
    Tearing ATL apart to find HTLV's sinister plans.
    Blood. 2020;135:887-889.

  270. TARLOCK K, Alonzo T, Wang YC, Gerbing RB, et al
    Prognostic Impact of CSF3R Mutations in Favorable Risk Childhood Acute Myeloid Leukemia.
    Blood. 2020 Mar 18. pii: 452717. doi: 10.1182/blood.2019004179.

  271. LI L, Mitra A, Cui K, Zhao B, et al
    Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell Acute Lymphoblastic Leukemia.
    Blood. 2020 Mar 16. pii: 452704. doi: 10.1182/blood.2019000794.
    PubMed     Abstract available

  272. HASSERJIAN RP, Steensma DP, Graubert TA, Ebert BL, et al
    Clonal Hematopoiesis and Measurable Residual Disease Assessment in Acute Myeloid Leukemia.
    Blood. 2020 Mar 13. pii: 452698. doi: 10.1182/blood.2019004770.
    PubMed     Abstract available

  273. LIU W, Xu J
    Microgranular acute promyelocytic leukemia with expression of T-cell markers mimicking mixed-phenotype acute leukemia.
    Blood. 2020;135:880.

  274. ABRISQUETA P, Bosch F
    Venetoclax-obinutuzumab: harnessing complexity.
    Blood. 2020;135:788-789.

    BCL-2 inhibition and AML: can we best Darwin?
    Blood. 2020;135:781-782.

  276. DINARDO CD, Tiong IS, Quaglieri A, MacRaild S, et al
    Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    Blood. 2020;135:791-803.
    PubMed     Abstract available

  277. KO TK, Javed A, Lee KL, Pathiraja TN, et al
    An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
    Blood. 2020 Mar 10. pii: 452673. doi: 10.1182/blood.2020004834.
    PubMed     Abstract available

  278. Rank CU, Toft N, Tuckuviene R, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018;131(22):2475-2484.
    Blood. 2020;135:780.

  279. ROWAN AG, Dillon R, Witkover A, Melamed A, et al
    Evolution of retrovirus-infected premalignant T-cell clones prior to Adult T-cell leukemia/lymphoma diagnosis.
    Blood. 2020 Mar 5. pii: 452636. doi: 10.1182/blood.2019002665.
    PubMed     Abstract available

  280. CHONG SJF, Davids MS
    Breaking through BCL-2 inhibition in CLL.
    Blood. 2020;135:709-711.

  281. DAVER N
    A bispecific approach to improving CAR T cells in AML.
    Blood. 2020;135:703-704.

  282. FU CL, Diacovo MJ
    Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen.
    Blood. 2020;135:778.

  283. GOTTSCHALK A, Glauche I, Cicconi S, Clark RE, et al
    Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
    Blood. 2020;135:766-769.

    February 2020
  284. DILLON R, Hills R, Freeman S, Potter N, et al
    Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
    Blood. 2020;135:680-688.
    PubMed     Abstract available

  285. DUFVA O, Koski J, Maliniemi P, Ianevski A, et al
    Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
    Blood. 2020;135:597-609.
    PubMed     Abstract available

  286. PAULI C, Liu Y, Rohde C, Cui C, et al
    Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for Acute Myeloid Leukemia cell proliferation.
    Blood. 2020 Feb 25. pii: 452567. doi: 10.1182/blood.2019004121.
    PubMed     Abstract available

  287. SOVERINI S, Bavaro L, De Benedittis C, Martelli M, et al
    Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
    Blood. 2020;135:534-541.
    PubMed     Abstract available

  288. DE SMEDT R, Morscio J, Reunes L, Roels J, et al
    Targeting cytokine and therapy induced PIM1 activation in T-cell acute lymphoblastic leukemia and lymphoma.
    Blood. 2020 Feb 13. pii: 452489. doi: 10.1182/blood.2019003880.
    PubMed     Abstract available

  289. KAGOTHO E, Chang H
    CML in megakaryocytic transformation and extramedullary infiltration.
    Blood. 2020;135:514.

  290. STRATI P, Schlette EJ, Solis Soto LM, Duenas DE, et al
    Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.
    Blood. 2020;135:510-513.

  291. ZHANG L, Li J, Xu H, Shao X, et al
    Myc-Miz-1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpalpha and Cebpdelta.
    Blood. 2020 Feb 7. pii: 441057. doi: 10.1182/blood.2019001863.
    PubMed     Abstract available

  292. PEDROSA F, Coustan-Smith E, Zhou Y, Cheng C, et al
    Reduced-dose-intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
    Blood. 2020 Feb 6. pii: 441001. doi: 10.1182/blood.2019004215.
    PubMed     Abstract available

  293. CIUREA SO, Kongtim P, Varma A, Rondon G, et al
    Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
    Blood. 2020;135:449-452.
    PubMed     Abstract available

  294. KWOK M, Oldreive C, Rawstron AC, Goel A, et al
    Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL.
    Blood. 2020;135:411-428.
    PubMed     Abstract available

    January 2020
  295. TISSINO E, Pozzo F, Benedetti D, Caldana C, et al
    CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
    Blood. 2020 Jan 31. pii: 440985. doi: 10.1182/blood.2019003179.
    PubMed     Abstract available

  296. MARTINO G, Ascani S
    Atypical intrasinusoidal bone marrow involvement by hairy cell leukemia.
    Blood. 2020;135:392.

  297. PAN J, Zuo S, Deng B, Xu X, et al
    Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.
    Blood. 2020;135:387-391.

  298. AL-SAWAF O, Lilienweiss E, Bahlo J, Robrecht S, et al
    High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
    Blood. 2020 Jan 27. pii: 440962. doi: 10.1182/blood.2019003451.

  299. WONG R, Tan TK, Amanda S, Ngoc PCT, et al
    Feed-forward Regulatory Loop Driven by IRF4 and NF-kappaB in Adult T-cell Leukemia/Lymphoma.
    Blood. 2020 Jan 23. pii: 431345. doi: 10.1182/blood.2019002639.
    PubMed     Abstract available

  300. BEZERRA MF, Lima AS, Pique-Borras MR, Silveira DR, et al
    Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis.
    Blood. 2020 Jan 23. pii: 440480. doi: 10.1182/blood.2019003339.

  301. ALDOSS I, Douer D
    How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 23. pii: 440580. doi: 10.1182/blood.2019002477.
    PubMed     Abstract available

  302. FABRE MA, McKerrell T, Zwiebel M, Vijayabaskar MS, et al
    Concordance for clonal hematopoiesis is limited in elderly twins.
    Blood. 2020;135:269-273.
    PubMed     Abstract available

  303. HANSEN JW, Pedersen DA, Larsen LA, Husby S, et al
    Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality.
    Blood. 2020;135:261-268.
    PubMed     Abstract available

  304. BARZ MJ, Hof J, Groeneveld-Krentz S, Loh JW, et al
    Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
    Blood. 2020 Jan 22. pii: 431280. doi: 10.1182/blood.2019002499.
    PubMed     Abstract available

  305. WOESSMANN W, Zimmermann M, Meinhardt A, Mueller S, et al
    Progressive or Relapsed Burkitt Lymphoma or Leukemia in Children and Adolescents after BFM-type First-line Therapy.
    Blood. 2020 Jan 21. pii: 431277. doi: 10.1182/blood.2019003591.
    PubMed     Abstract available

    How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation.
    Blood. 2020 Jan 21. pii: 431276. doi: 10.1182/blood.2019003566.
    PubMed     Abstract available

  307. HE X, Feng Z, Ma J, Ling S, et al
    Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia.
    Blood. 2020 Jan 17. pii: 431045. doi: 10.1182/blood.2019002779.
    PubMed     Abstract available

  308. BLOMBERY P, Thompson E, Nguyen T, Birkinshaw RW, et al
    Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
    Blood. 2020 Jan 17. pii: 431046. doi: 10.1182/blood.2019004205.

  309. MEYER SE
    MicroRNA immunomodulating therapeutics.
    Blood. 2020;135:155-156.

  310. HALE DA, Krause JR
    Unexpected lymph node finding in a patient with essential thrombocythemia.
    Blood. 2020;135:154.

  311. ALDOSS I, Forman SJ
    How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.
    Blood. 2020 Jan 3. pii: 430058. doi: 10.1182/blood.2019002132.
    PubMed     Abstract available

  312. MORSCIO J, Van Vlierberghe P
    Chemotherapy at the wheel of ALL relapse.
    Blood. 2020;135:4-5.

  313. SWANSON HD, Panetta JC, Barker PJ, Liu Y, et al
    Predicting success of desensitization after pegaspargase allergy.
    Blood. 2020;135:71-75.

  314. LEVIS M, Shi W, Chang K, Laing C, et al
    FLT3 inhibitors added to induction therapy induce deeper remissions.
    Blood. 2020;135:75-78.

  315. WANG N, Hu X, Cao W, Li C, et al
    Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
    Blood. 2020;135:17-27.
    PubMed     Abstract available

    December 2019
  316. FOURNIER E, Duployez N, Ducourneau B, Raffoux E, et al
    Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial.
    Blood. 2019 Dec 27. pii: 430032. doi: 10.1182/blood.2019003471.
    PubMed     Abstract available

  317. BYRD JC, Wierda WG, Schuh A, Devereux S, et al
    Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
    Blood. 2019 Dec 26. pii: 430030. doi: 10.1182/blood.2018884940.
    PubMed     Abstract available

    The curious incident of TdT-mediated mutations in AML.
    Blood. 2019;134:2229-2231.

  319. BORROW J, Dyer SA, Akiki S, Griffiths MJ, et al
    Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT.
    Blood. 2019;134:2291-2303.
    PubMed     Abstract available

  320. ROBOZ GJ, DiNardo CD, Stein EM, de Botton S, et al
    Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
    Blood. 2019 Dec 16. pii: 429665. doi: 10.1182/blood.2019002140.
    PubMed     Abstract available

  321. TRAER E
    Reducing acetyl-CoA enhances BET inhibition.
    Blood. 2019;134:2122-2123.

  322. GARDNER RA, Ceppi F, Rivers J, Annesley C, et al
    Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
    Blood. 2019;134:2149-2158.
    PubMed     Abstract available

  323. DOHNER K, Thiede C, Jahn N, Panina E, et al
    Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia.
    Blood. 2019 Dec 11. pii: 429642. doi: 10.1182/blood.2019002697.
    PubMed     Abstract available

  324. STANULLA M, Cave H, Moorman AV
    IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?
    Blood. 2019 Dec 10. pii: 429640. doi: 10.1182/blood.2019000813.
    PubMed     Abstract available

  325. SU YL, Wang X, Mann M, Adamus TP, et al
    Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-kB-Driven Inflammation and Leukemia Progression in Vivo.
    Blood. 2019 Dec 5. pii: 429548. doi: 10.1182/blood.2019002045.
    PubMed     Abstract available

  326. OLIN RL
    Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.
    Blood. 2019;134:2013-2021.
    PubMed     Abstract available

    November 2019
    CLL: deep dive for residual cells by NGS matters.
    Blood. 2019;134:1883-1884.

  328. FENNELL KA, Bell CC, Dawson MA
    Epigenetic therapies in acute myeloid leukemia: where to from here?
    Blood. 2019;134:1891-1901.
    PubMed     Abstract available

  329. THOMPSON PA, Srivastava J, Peterson C, Strati P, et al
    Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
    Blood. 2019;134:1951-1959.
    PubMed     Abstract available

  330. DINARDO CD, Wei AH
    How I treat acute myeloid leukemia in the era of new drugs.
    Blood. 2019 Nov 25. pii: 428884. doi: 10.1182/blood.2019001239.
    PubMed     Abstract available

  331. KAY NE, Hanson CA
    B-cell prolymphocytic leukemia has 3 subsets.
    Blood. 2019;134:1777-1778.

  332. MCCURDY SR, Luznik L
    How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.
    Blood. 2019;134:1802-1810.
    PubMed     Abstract available

  333. WOYACH JA
    Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
    Blood. 2019;134:1796-1801.
    PubMed     Abstract available

  334. DWYRE DM, Osman M
    AML with inv(16) with numerous Charcot-Leyden crystals.
    Blood. 2019;134:1876.

  335. CHONG EA, Levine BL, Grupp SA, Davis MM, et al
    CAR T cell viability release testing and clinical outcomes: is there a lower limit?
    Blood. 2019;134:1873-1875.

  336. TEACHEY DT, O'Connor D
    How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children.
    Blood. 2019 Nov 18. pii: 428813. doi: 10.1182/blood.2019001557.
    PubMed     Abstract available

  337. CLAUDIANI S, Metelli S, Kamvar R, Szydlo R, et al
    Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).
    Blood. 2019;134.
    PubMed     Abstract available

  338. ROLLIG C, Kramer M, Schliemann C, Mikesch JH, et al
    Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Blood. 2019;134.
    PubMed     Abstract available

  339. TAM CS, Siddiqi T, Allan JN, Kipps TJ, et al
    Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study.
    Blood. 2019;134.
    PubMed     Abstract available

  340. TANAKA T, Morita K, Wang F, Little L, et al
    Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2019;134.
    PubMed     Abstract available

  341. SHARMAN JP, Banerji V, Fogliatto LM, Herishanu Y, et al
    ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).
    Blood. 2019;134.
    PubMed     Abstract available

  342. STATLER A, Hobbs BP, Radivoyevitch T, Siebenaller C, et al
    The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.
    Blood. 2019;134.
    PubMed     Abstract available

  343. JAIN N, Keating MJ, Thompson PA, Ferrajoli A, et al
    Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL).
    Blood. 2019;134.
    PubMed     Abstract available

  344. CIUREA SO, Varma A, Kongtim P, Srour S, et al
    Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis.
    Blood. 2019;134.
    PubMed     Abstract available

  345. SHIMA H, Kada A, Tanizawa A, Yuza Y, et al
    Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study).
    Blood. 2019;134.
    PubMed     Abstract available

  346. REA D, Nicolini FE, Tulliez M, Rousselot P, et al
    Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
    Blood. 2019;134.
    PubMed     Abstract available

  347. LINDSLEY RC, Gibson CJ, Murdock HM, Stone RM, et al
    Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML).
    Blood. 2019;134.
    PubMed     Abstract available

  348. SHANAFELT TD, Wang V, Kay NE, Hanson CA, et al
    Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.
    Blood. 2019;134.
    PubMed     Abstract available

  349. DIRAL E, Le Coutre P, Gottardi EM, Elena C, et al
    Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR.
    Blood. 2019;134.
    PubMed     Abstract available

  350. LAMPSON BL, Tyekucheva S, Crombie JL, Kim AI, et al
    Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).
    Blood. 2019;134.
    PubMed     Abstract available

  351. SMITH CC, Levis MJ, Perl AE, Martinelli G, et al
    Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial.
    Blood. 2019;134.
    PubMed     Abstract available

  352. RADICH J, Yeung C, Wu D
    New approaches to molecular monitoring in CML (and other diseases).
    Blood. 2019;134:1578-1584.
    PubMed     Abstract available

  353. TARUMOTO Y, Lin S, Wang J, Milazzo JP, et al
    Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.
    Blood. 2019 Nov 1. pii: 422697. doi: 10.1182/blood.2019001576.
    PubMed     Abstract available

    October 2019
  354. DUPLOYEZ N, Willekens C, Plo I, Marceau-Renaut A, et al
    Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
    Blood. 2019 Oct 31. pii: 422691. doi: 10.1182/blood.2019003206.

  355. SUN YM, Wang WT, Zeng ZC, Chen TQ, et al
    circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression.
    Blood. 2019;134:1533-1546.
    PubMed     Abstract available

  356. LI B, Brady SW, Ma X, Shen S, et al
    Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
    Blood. 2019 Oct 24. pii: 422540. doi: 10.1182/blood.2019002220.
    PubMed     Abstract available

    Lifting the veil on germline DDX41 mutations.
    Blood. 2019;134:1368-1370.

    A sobering "check" on immune checkpoint inhibitors.
    Blood. 2019;134:1366-1367.

  359. BURT R, Dey A, Aref S, Aguiar M, et al
    Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
    Blood. 2019;134:1415-1429.
    PubMed     Abstract available

  360. SEBERT M, Passet M, Raimbault A, Rahme R, et al
    Germline DDX41 mutations define a significant entity within adult MDS/AML patients.
    Blood. 2019;134:1441-1444.
    PubMed     Abstract available

  361. BORROW J, Dyer SA, Akiki S, Griffiths MJ, et al
    Terminal Deoxynucleotidyl Transferase Promotes Acute Myeloid Leukemia By Priming FLT3-ITD Replication Slippage.
    Blood. 2019 Oct 17. pii: 421184. doi: 10.1182/blood.2019001238.
    PubMed     Abstract available

    En-Abl-ing treatment of "Ph-like" ALL?
    Blood. 2019;134:1277-1278.

  363. THANGAVELU G, Du J, Paz KG, Loschi M, et al
    Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.
    Blood. 2019 Oct 15. pii: 387148. doi: 10.1182/blood.2019000032.
    PubMed     Abstract available

  364. PATEL AB, Franzini A, Leroy E, Kim SJ, et al
    JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
    Blood. 2019 Oct 11. pii: 381160. doi: 10.1182/blood.2019001385.
    PubMed     Abstract available

  365. MUSHTAQ MU, Matson DR
    Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis.
    Blood. 2019;134:1270.

  366. JIANG Y, Hu T, Wang T, Shi X, et al
    AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia.
    Blood. 2019 Oct 10. pii: 375147. doi: 10.1182/blood.2019001076.
    PubMed     Abstract available

  367. ELITZUR S, Izraeli S
    Genes driving bad luck.
    Blood. 2019;134:1199-1200.

    T-PLL: harmonizing criteria for research.
    Blood. 2019;134:1113-1114.

  369. MORISHIMA T, Krahl AC, Nasri M, Xu Y, et al
    LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
    Blood. 2019;134:1159-1175.
    PubMed     Abstract available

    September 2019

  370. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548-1559.
    Blood. 2019;134:1111.

  371. SUKSWAI N, Thirabanjasak D
    B-lymphoblastic leukemia/lymphoma with an unusual appendiceal involvement.
    Blood. 2019;134:1110.

  372. LUNNING M, Vose J, Nastoupil L, Fowler N, et al
    Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Blood. 2019 Sep 26. pii: blood.2019002118. doi: 10.1182/blood.2019002118.
    PubMed     Abstract available

  373. RUCKER FG, Agrawal M, Corbacioglu A, Weber D, et al
    Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.
    Blood. 2019 Sep 25. pii: blood.2019001425. doi: 10.1182/blood.2019001425.
    PubMed     Abstract available

  374. PATEL K, Danilov A, Pagel JM
    Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.
    Blood. 2019 Sep 25. pii: blood.2019001795. doi: 10.1182/blood.2019001795.
    PubMed     Abstract available

  375. KHATRI SS, Kim AS
    Li-Fraumeni syndrome presenting as precursor B lymphoblastic leukemia mimicking intravascular large B-cell lymphoma.
    Blood. 2019;134:993.

  376. ASSLABER D, Qi Y, Maeding N, Steiner M, et al
    B-cell specific IRF4 deletion accelerates Chronic Lymphocytic Leukemia development by enhanced tumor immune evasion.
    Blood. 2019 Sep 19. pii: blood.2019000973. doi: 10.1182/blood.2019000973.
    PubMed     Abstract available

  377. GONZALEZ-GARCIA S, Mosquera M, Fuentes P, Palumbo T, et al
    IL-7R is essential for leukemia-initiating cell activity and pathogenesis of T-cell acute lymphoblastic leukemia.
    Blood. 2019 Sep 17. pii: blood.2019000982. doi: 10.1182/blood.2019000982.
    PubMed     Abstract available

  378. CHAPIRO E, Pramil E, Diop M, Roos-Weil D, et al
    Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
    Blood. 2019 Sep 16. pii: blood.2019001187. doi: 10.1182/blood.2019001187.
    PubMed     Abstract available

  379. JULIUSSON G, Hagberg O, Lazarevic VL, Olander E, et al
    Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.
    Blood. 2019 Sep 12. pii: blood.2019001728. doi: 10.1182/blood.2019001728.

  380. PARK CS, Lewis AH, Chen TJ, Bridges CS, et al
    KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells.
    Blood. 2019 Sep 12. pii: blood.2018875922. doi: 10.1182/blood.2018875922.
    PubMed     Abstract available

    Illuminating neutrophilic myeloid neoplasms.
    Blood. 2019;134:846-848.

  382. TAM CS, Trotman J, Opat S, Burger JA, et al
    Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
    Blood. 2019;134:851-859.
    PubMed     Abstract available

  383. BATTIPAGLIA G, Labopin M, Kroger N, Vitek A, et al
    Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
    Blood. 2019;134:892-899.
    PubMed     Abstract available

  384. BUENO C, Tejedor JR, Bashford-Rogers R, Gonzalez-Silva L, et al
    Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL.
    Blood. 2019;134:900-905.

  385. HIJIYA N, Maschan A, Rizzari C, Shimada H, et al
    Phase 2 Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
    Blood. 2019 Sep 11. pii: blood.2019000069. doi: 10.1182/blood.2019000069.
    PubMed     Abstract available

  386. BROUX M, Prieto C, Demeyer S, Vanden Bempt M, et al
    Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
    Blood. 2019 Sep 6. pii: blood.2019000015. doi: 10.1182/blood.2019000015.
    PubMed     Abstract available

    Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia.
    Blood. 2019 Sep 5. pii: blood.2019001750. doi: 10.1182/blood.2019001750.
    PubMed     Abstract available

    August 2019
  388. LEFEBVRE T, Mauvieux L
    A gelatinous leukemia.
    Blood. 2019;134:785.

  389. RAUCH DA, Conlon KC, Janakiram M, Brammer JE, et al
    Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade.
    Blood. 2019 Aug 29. pii: blood.2019002038. doi: 10.1182/blood.2019002038.
    PubMed     Abstract available

  390. PERL AE
    Availability of FLT3 inhibitors: how do we use them?
    Blood. 2019;134:741-745.
    PubMed     Abstract available

  391. Steele AJ, Prentice AG, Hoffbrand AV, et al. 2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood. 2009;114(6):1217-1225.
    Blood. 2019;134:719-721.

  392. WANG HY, Hinds BR
    Cutaneous composite small lymphocytic lymphoma and primary cutaneous follicle center lymphoma.
    Blood. 2019;134:717.

  393. TANASI I, Ba I, Sirvent N, Braun T, et al
    Efficacy of Tyrosine Kinase Inhibitors in Ph-like Acute Lymphoblastic Leukemia harboring ABL-class Rearrangements.
    Blood. 2019 Aug 21. pii: blood.2019001244. doi: 10.1182/blood.2019001244.

  394. Oral arsenic for acute promyelocytic leukemia.
    Blood. 2019;134:659.

  395. QUINQUENEL A, Fornecker LM, Letestu R, Ysebaert L, et al
    Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
    Blood. 2019;134:641-644.
    PubMed     Abstract available

  396. JANKE LJ, Van Driest SL, Portera MV, Atreya RV, et al
    Hypertension is a modifiable risk-factor for osteonecrosis in acute lymphoblastic leukemia.
    Blood. 2019 Aug 13. pii: blood.2019000006. doi: 10.1182/blood.2019000006.

  397. CHEN Y, Chen L, Yu J, Ghia EM, et al
    Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-kappaB To Repress Autocrine STAT3-Activation In Chronic Lymphocytic Leukemia.
    Blood. 2019 Aug 13. pii: blood.2019001366. doi: 10.1182/blood.2019001366.
    PubMed     Abstract available

  398. ZHU Y, He X, Lin YC, Dong H, et al
    Targeting PRMT1-Mediated FLT3 Methylation Disrupts Maintenance of MLL- rearranged Acute Lymphoblastic Leukemia.
    Blood. 2019 Aug 8. pii: blood.2019002457. doi: 10.1182/blood.2019002457.
    PubMed     Abstract available

  399. VENDITTI A, Piciocchi A, Candoni A, Melillo L, et al
    Blood. 2019 Aug 8. pii: blood.2018886960. doi: 10.1182/blood.2018886960.
    PubMed     Abstract available

    FLT3-ITD gets by with a little help from PRMT1.
    Blood. 2019;134:498-500.

  401. KLEIN U
    Resolving PI3K-delta inhibitor resistance in CLL.
    Blood. 2019;134:496-498.

  402. COFFY S, Shi M
    Giant intracytoplasmic inclusions in a T-cell large granular lymphocytic leukemia patient with acute severe anemia.
    Blood. 2019;134:492.

  403. CHIANG CL, Goswami S, Frissora FW, Xie Z, et al
    ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
    Blood. 2019;134:432-444.
    PubMed     Abstract available

    July 2019
  404. BROWN AL, de Smith AJ, Gant VU, Yang W, et al
    Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome.
    Blood. 2019 Jul 26. pii: blood.2018890764. doi: 10.1182/blood.2018890764.
    PubMed     Abstract available

  405. HERMANS SJF, Sandberg Y
    T-cell prolymphocytic leukemia presenting as ascites.
    Blood. 2019;134:411.

  406. STUANI L, Sarry JE
    Help from outside: cysteine to survive in AML.
    Blood. 2019;134:336-338.

    Triple-mutant AML: too clever by HLF?
    Blood. 2019;134:222-224.

  408. CHIANG MY
    Finding ARIEL under the sea of T-ALL circuits.
    Blood. 2019;134:219-221.

  409. LI W, Cooley LD, August KJ, Richardson AI, et al
    Cuplike nuclear morphology is highly associated with IKZF1 deletion in pediatric precursor B-cell ALL.
    Blood. 2019;134:324-329.

  410. GOCHO Y, Yang JJ
    Genetic Defects in Hematopoietic Transcription Factors and Predisposition to Acute Lymphoblastic Leukemia.
    Blood. 2019 Jul 16. pii: blood.2018852400. doi: 10.1182/blood.2018852400.
    PubMed     Abstract available

  411. VOGIATZI F, Winterberg D, Lenk L, Buchmann S, et al
    Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
    Blood. 2019 Jul 16. pii: blood.2019000904. doi: 10.1182/blood.2019000904.

  412. ROSSI D
    Quest of biomarkers for venetoclax-treated CLL.
    Blood. 2019;134:97-98.

  413. STABER PB, Herling M, Bellido M, Jacobsen ED, et al
    Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).
    Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402.
    PubMed     Abstract available

  414. GIACOPELLI B, Zhao Q, Ruppert AS, Agyeman A, et al
    Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.
    Blood. 2019 Jul 10. pii: blood.2019000490. doi: 10.1182/blood.2019000490.
    PubMed     Abstract available

  415. LUCENA-ARAUJO AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR MD, et al
    Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.
    Blood. 2019 Jul 10. pii: blood.2019000239. doi: 10.1182/blood.2019000239.
    PubMed     Abstract available

  416. Nguyen TD, Shaid S, Vakhrusheva O, et al. Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. Blood. 2019;133(2):168-179.
    Blood. 2019;134:94.

  417. MILL CP, Fiskus W, DiNardo CD, Qian Y, et al
    RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1.
    Blood. 2019;134:59-73.
    PubMed     Abstract available

  418. SHANMUGANATHAN N, Braley JA, Yong ASM, Hiwase DK, et al
    Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.
    Blood. 2019;134:85-89.

  419. HU T, Morita K, Hill MC, Jiang Y, et al
    PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells.
    Blood. 2019 Jul 3. pii: blood.2018888255. doi: 10.1182/blood.2018888255.
    PubMed     Abstract available

    June 2019
  420. DI PAOLA J, Porter CC
    ETV6-Related Thrombocytopenia and Leukemia Predisposition.
    Blood. 2019 Jun 27. pii: blood.2019852418. doi: 10.1182/blood.2019852418.
    PubMed     Abstract available

  421. COUTRE S
    A one-two punch with VO KOs CLL.
    Blood. 2019;133:2737-2738.

  422. ROTUNNO G, Mannarelli C, Brogi G, Pacilli A, et al
    Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.
    Blood. 2019;133:2802-2808.

  423. GODLEY LA
    FouNdER mutations confer risk for leukemias.
    Blood. 2019;133:2636-2638.

  424. HEUSER M, Lai CK
    Message from the void: MRD analysis from ctDNA.
    Blood. 2019;133:2631-2633.

  425. CHIODIN G, Forconi F
    Hedgehog activation in CLL.
    Blood. 2019;133:2628-2630.

  426. HE X, Zhu Y, Lin YC, Li M, et al
    PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD(+) Acute Myeloid Leukemia.
    Blood. 2019 Jun 19. pii: blood.2019001282. doi: 10.1182/blood.2019001282.
    PubMed     Abstract available

  427. Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522-1531.
    Blood. 2019;133:2625.

  428. KWON R, Duffield AS
    HTLV-1-associated adult T-cell leukemia/lymphoma with disseminated strongyloidiasis.
    Blood. 2019;133:2623.

    B-1 progenitor acute lymphoid leukemia.
    Blood. 2019;133:2557-2558.

  430. RUDORF A, Muller TA, Klingeberg C, Kreutmair S, et al
    NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.
    Blood. 2019 Jun 11. pii: blood.2018883140. doi: 10.1182/blood.2018883140.
    PubMed     Abstract available

    May 2019
  431. AHN IE, Basumallik N, Tian X, Soto S, et al
    Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.
    Blood. 2019;133:2452-2455.

    RETRACTION: Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood. 2006
    Blood. 2019 May 24. pii: blood-2019-05-901215. doi: 10.1182/blood-2019-05-901215

  433. SYKES SM
    NCAM1 supports therapy resistance and LSC function in AML.
    Blood. 2019;133:2247-2248.

  434. MACIOCIA PM, Pule MA
    Anti-CD1a CAR T cells to selectively target T-ALL.
    Blood. 2019;133:2246-2247.

  435. DIECK CL, Ferrando A
    Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
    Blood. 2019;133:2263-2268.
    PubMed     Abstract available

  436. SASCA D, Szybinski J, Schuler A, Shah V, et al
    NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
    Blood. 2019;133:2305-2319.
    PubMed     Abstract available

  437. ZHU HH, Hu J, Lo Coco F, Jin J, et al
    The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia.
    Blood. 2019 May 21. pii: blood.2019000760. doi: 10.1182/blood.2019000760.
    PubMed     Abstract available

  438. JONES CL, Stevens BM, D'Alessandro A, Culp-Hill R, et al
    Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II.
    Blood. 2019 May 17. pii: blood.2019898114. doi: 10.1182/blood.2019898114.
    PubMed     Abstract available

  439. YANG J, Gabali A
    Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome.
    Blood. 2019;133:2243.

  440. MAGGI M, Scotti C
    HAP1 loss in l-asparaginase resistance.
    Blood. 2019;133:2116-2118.

  441. LEE JK, Kang S, Wang X, Rosales JL, et al
    HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.
    Blood. 2019;133:2222-2232.
    PubMed     Abstract available

  442. KARSCHNIA P, Jordan JT, Forst DA, Arrillaga-Romany IC, et al
    Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
    Blood. 2019;133:2212-2221.
    PubMed     Abstract available

  443. VAN BRUGGEN JAC, Martens AWJ, Fraietta JA, Hofland T, et al
    Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy.
    Blood. 2019 May 10. pii: blood.2018885863. doi: 10.1182/blood.2018885863.
    PubMed     Abstract available

  444. GARG S, Reyes-Palomares A, He L, Bergeron A, et al
    Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML.
    Blood. 2019 May 10. pii: blood.2018862383. doi: 10.1182/blood.2018862383.
    PubMed     Abstract available

  445. TAN SH, Leong WZ, Ngoc PCT, Tan TK, et al
    The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.
    Blood. 2019 May 10. pii: blood.2018874503. doi: 10.1182/blood.2018874503.
    PubMed     Abstract available

    Ibrutinib is safer than we think.
    Blood. 2019;133:2006-2007.

    Ibrutinib: the home run for cure in CLL?
    Blood. 2019;133:2003-2004.

  448. BYRD JC, Hillmen P, O'Brien S, Barrientos JC, et al
    Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
    Blood. 2019;133:2031-2042.
    PubMed     Abstract available

    April 2019
  449. DERRIEUX C, Tarfi S
    Azurophilic granular blasts are not always part of myeloid lineage: an atypical case of BCP acute lymphoblastic leukemia.
    Blood. 2019;133:1919.

  450. BJORKHOLM M, Edgren G, Dickman PW
    Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and USA.
    Blood. 2019 Apr 25. pii: blood.2019001168. doi: 10.1182/blood.2019001168.

  451. ROBERTS AW, Ma S, Kipps TJ, Coutre SE, et al
    Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.
    Blood. 2019 Apr 25. pii: blood.2018882555. doi: 10.1182/blood.2018882555.
    PubMed     Abstract available

  452. SCHEFFOLD A, Jebaraj BMC, Tausch E, Bloehdorn J, et al
    IGF1R as druggable target mediating PI3K-delta inhibitor resistance in a murine model of chronic lymphocytic leukemia.
    Blood. 2019 Apr 22. pii: blood.2018881029. doi: 10.1182/blood.2018881029.
    PubMed     Abstract available

  453. PLESA A, Sujobert P
    Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion.
    Blood. 2019;133:1789.

    Context-specific tumor suppression by PHF6.
    Blood. 2019;133:1698-1700.

  455. FORERO-TORRES A, Ramchandren R, Yacoub A, Wertheim MS, et al
    Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies.
    Blood. 2019;133:1742-1752.
    PubMed     Abstract available

  456. CURRAN E, Stock W
    Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
    Blood. 2019;133:1715-1719.
    PubMed     Abstract available

  457. JUTZI JS, Basu T, Pellmann M, Kaiser S, et al
    Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
    Blood. 2019;133:1766-1777.
    PubMed     Abstract available

  458. YIN M, Chung YJ, Lindsley RC, Walker RL, et al
    Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.
    Blood. 2019 Apr 16. pii: blood.2018864173. doi: 10.1182/blood.2018864173.
    PubMed     Abstract available

  459. ZHAN Y, Teruya-Feldstein J
    Immune dysregulation: EBV(+) DLBCL and HLH in a patient with T-LGL.
    Blood. 2019;133:1695.

  460. HAY KA, Gauthier J, Hirayama AV, Voutsinas JM, et al
    Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Blood. 2019;133:1652-1663.
    PubMed     Abstract available

  461. DOUGLAS SPM, Siipola P, Kovanen P, Pyorala M, et al
    ERCC6L2 defines a novel entity within inherited acute myeloid leukemia.
    Blood. 2019 Apr 1. pii: blood-2019-01-896233. doi: 10.1182/blood-2019-01-896233.

  462. NAKAMURA S, Yokoyama K, Shimizu E, Yusa N, et al
    Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
    Blood. 2019 Apr 1. pii: blood-2018-10-880690. doi: 10.1182/blood-2018-10-880690.
    PubMed     Abstract available

    March 2019
  463. GHIA EM, Rassenti LZ, Neuberg DS, Blanco A, et al
    Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.
    Blood. 2019 Mar 28. pii: blood-2018-09-873695. doi: 10.1182/blood-2018-09-873695
    PubMed     Abstract available

  464. LEVIS M
    Arsenic and old FLT3.
    Blood. 2019;133:1392-1393.

  465. WEI AH
    Maintenance therapy for AML: are we there yet?
    Blood. 2019;133:1390-1392.

  466. GOHIL SH, Wu CJ
    Dissecting CLL through high-dimensional single-cell technologies.
    Blood. 2019;133:1446-1456.
    PubMed     Abstract available

  467. ESNAULT C, Rahme R, Rice KL, Berthier C, et al
    FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.
    Blood. 2019;133:1495-1506.
    PubMed     Abstract available

  468. GOLAY J, Valgardsdottir R, Musaraj G, Giupponi D, et al
    Human neutrophils express low levels of FcgammaRIIIA, which plays a role in PMN activation.
    Blood. 2019;133:1395-1405.
    PubMed     Abstract available

  469. HULS G, Chitu DA, Havelange V, Jongen-Lavrencic M, et al
    Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
    Blood. 2019;133:1457-1464.
    PubMed     Abstract available

  470. HIJIYA N, Suttorp M
    How I Treat Chronic Myeloid Leukemia in Children and Adolescents.
    Blood. 2019 Mar 27. pii: blood.2018882233. doi: 10.1182/blood.2018882233.
    PubMed     Abstract available

  471. SARASIN A, Quentin S, Droin N, Sahbatou M, et al
    Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum.
    Blood. 2019 Mar 26. pii: blood-2019-01-895698. doi: 10.1182/blood-2019-01-895698

  472. CARGO C, Cullen M, Taylor J, Short M, et al
    The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
    Blood. 2019;133:1325-1334.
    PubMed     Abstract available

  473. ZEISER R, Vago L
    Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.
    Blood. 2019;133:1290-1297.
    PubMed     Abstract available

  474. LIU H
    Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged.
    Blood. 2019;133:1265.

    Hairy cell leukemia coexistent with chronic lymphocytic leukemia.
    Blood. 2019;133:1264.

    Intricacies of CLL cytogenetic complexity.
    Blood. 2019;133:1168-1170.

    CDK9 and mTOR: trading places.
    Blood. 2019;133:1167-1168.

  478. FLINN IW, Gribben JG, Dyer MJS, Wierda W, et al
    Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Blood. 2019 Mar 12. pii: blood-2019-01-896290. doi: 10.1182/blood-2019-01-896290
    PubMed     Abstract available

  479. HAFERLACH T, Meggendorfer M
    More than a fusion gene: the RUNX1-RUNX1T1 AML.
    Blood. 2019;133:1006-1007.

  480. BYRD JC
    Targeting CD20 takes the backseat in CLL.
    Blood. 2019;133:1003-1004.

  481. MERKENSCHLAGER J, Eksmond U, Danelli L, Attig J, et al
    MHC class II cell-autonomously regulates self-renewal and differentiation of normal and malignant B cells.
    Blood. 2019;133:1108-1118.
    PubMed     Abstract available

  482. PRONK E, Raaijmakers MHGP
    The mesenchymal niche in MDS.
    Blood. 2019;133:1031-1038.
    PubMed     Abstract available

  483. TANAKA TN, Bejar R
    MDS overlap disorders and diagnostic boundaries.
    Blood. 2019;133:1086-1095.
    PubMed     Abstract available

  484. OGAWA S
    Genetics of MDS.
    Blood. 2019;133:1049-1059.
    PubMed     Abstract available

    February 2019
  485. BROWN JR, O'Brien S, Kingsley CD, Eradat H, et al
    Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
    Blood. 2019;133:990-992.

  486. MORANDE PE, Sivina M, Uriepero A, Seija N, et al
    Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
    Blood. 2019 Feb 27. pii: blood-2018-09-876292. doi: 10.1182/blood-2018-09-876292
    PubMed     Abstract available

  487. SANZ MA, Fenaux P, Tallman MS, Estey EH, et al
    Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
    Blood. 2019 Feb 25. pii: blood-2019-01-894980. doi: 10.1182/blood-2019-01-894980
    PubMed     Abstract available

  488. KAUFMANN KB, Garcia-Prat L, Liu Q, Ng SWK, et al
    A stemness screen reveals C3orf54/INKA1 as a promoter of human leukemia stem cell latency.
    Blood. 2019 Feb 22. pii: blood-2018-10-881441. doi: 10.1182/blood-2018-10-881441
    PubMed     Abstract available

  489. SANCHEZ-MARTINEZ D, Baroni ML, Gutierrez-Aguera F, Roca-Ho H, et al
    Fratricide-resistant CD1a-specific CAR T-cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
    Blood. 2019 Feb 22. pii: blood-2018-10-882944. doi: 10.1182/blood-2018-10-882944
    PubMed     Abstract available

  490. ROSSI D
    FBXW7 is a biologically validated cancer driver gene for CLL.
    Blood. 2019;133:774-776.

  491. CLOSE V, Close W, Kugler SJ, Reichenzeller M, et al
    FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.
    Blood. 2019;133:830-839.
    PubMed     Abstract available

    Yet another susceptibility variant for ALL: what's next?
    Blood. 2019;133:628-629.

    IDH2 inhibition: another piece to the puzzle.
    Blood. 2019;133:625-626.

  494. STERNER RM, Sakemura R, Cox MJ, Yang N, et al
    GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
    Blood. 2019;133:697-709.
    PubMed     Abstract available

  495. MCRAE HM, Garnham AL, Hu Y, Witkowski MT, et al
    PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.
    Blood. 2019 Feb 12. pii: blood-2018-07-860726. doi: 10.1182/blood-2018-07-860726
    PubMed     Abstract available

  496. SMITH CC
    Roman warfare: targeting of support cells in AML.
    Blood. 2019;133:506-507.

    January 2019
    Highs and lows of minimal residual disease in CLL.
    Blood. 2019;133:386-388.

  498. LANGERAK AW, Ritgen M, Goede V, Robrecht S, et al
    Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
    Blood. 2019;133:494-497.

  499. NIEMEYER CM, Flotho C
    Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Blood. 2019 Jan 22. pii: blood-2018-11-844688. doi: 10.1182/blood-2018-11-844688
    PubMed     Abstract available

  500. STOCK W, Luger SM, Advani AS, Yin J, et al
    A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
    Blood. 2019 Jan 18. pii: blood-2018-10-881961. doi: 10.1182/blood-2018-10-881961
    PubMed     Abstract available

  501. HALLNER A, Bernson E, Hussein BA, Sander FE, et al
    The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
    Blood. 2019 Jan 15. pii: blood-2018-09-874990. doi: 10.1182/blood-2018-09-874990
    PubMed     Abstract available

  502. STEPHENS DM, Byrd JC
    How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
    Blood. 2019 Jan 14. pii: blood-2018-11-846808. doi: 10.1182/blood-2018-11-846808
    PubMed     Abstract available

  503. XIE W, Xu J
    Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia.
    Blood. 2019;133:182.

  504. TORUNER GA, Thakral B
    Relapsed NPM1 mutated acute myeloid leukemia with PDGFRA rearrangement.
    Blood. 2019;133:181.

  505. SARRAF YAZDY M, Mato AR, Cheson BD
    Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
    Blood. 2019;133:121-129.
    PubMed     Abstract available

  506. CHRISTEN F, Hoyer K, Yoshida K, Hou HA, et al
    Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
    Blood. 2019 Jan 4. pii: blood-2018-05-852822. doi: 10.1182/blood-2018-05-852822.
    PubMed     Abstract available

    Venetoclax in AML: aiming for "just right".
    Blood. 2019;133:3-4.

  508. BALIAKAS P, Jeromin S, Iskas M, Puiggros A, et al
    Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact.
    Blood. 2019 Jan 2. pii: blood-2018-09-873083. doi: 10.1182/blood-2018-09-873083.
    PubMed     Abstract available

    December 2018
  509. BEAUCHAMP EM, Abedin SM, Radecki SG, Fischietti M, et al
    Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
    Blood. 2018 Dec 26. pii: blood-2018-08-870089. doi: 10.1182/blood-2018-08-870089
    PubMed     Abstract available

  510. SCHLENK RF, Weber D, Fiedler W, Salih HR, et al
    Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
    Blood. 2018 Dec 18. pii: blood-2018-08-869453. doi: 10.1182/blood-2018-08-869453
    PubMed     Abstract available

  511. BILICH T, Nelde A, Bichmann L, Roerden M, et al
    The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
    Blood. 2018 Dec 10. pii: blood-2018-07-866830. doi: 10.1182/blood-2018-07-866830
    PubMed     Abstract available

  512. BURGER JA, Sivina M, Jain N, Kim E, et al
    Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.
    Blood. 2018 Dec 7. pii: blood-2018-10-879429. doi: 10.1182/blood-2018-10-879429.
    PubMed     Abstract available

  513. PASSET M, Boissel N, Sigaux F, Saillard C, et al
    PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.
    Blood. 2018 Dec 3. pii: blood-2018-10-882142. doi: 10.1182/blood-2018-10-882142.

  514. QIAN M, Xu H, Perez-Andreu V, Roberts KG, et al
    Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics.
    Blood. 2018 Dec 3. pii: blood-2018-07-862946. doi: 10.1182/blood-2018-07-862946.
    PubMed     Abstract available

  515. STEIN EM, DiNardo CD, Fathi AT, Pollyea DA, et al
    Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
    Blood. 2018 Dec 3. pii: blood-2018-08-869008. doi: 10.1182/blood-2018-08-869008.
    PubMed     Abstract available

    November 2018
  516. KLAIRMONT MM, Choi JK
    Mixed-phenotype acute leukemia, T/megakaryoblastic.
    Blood. 2018;132:2418.

  517. NGUYEN TD, Shaid S, Vakhrusheva O, Koschade SE, et al
    Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy.
    Blood. 2018 Nov 29. pii: blood-2018-02-833475. doi: 10.1182/blood-2018-02-833475
    PubMed     Abstract available

  518. JIANG W, Lee SH
    Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes.
    Blood. 2018;132:2314.

  519. BROWN P, Pieters R, Biondi A
    How I treat infant leukemia.
    Blood. 2018 Nov 20. pii: blood-2018-04-785980. doi: 10.1182/blood-2018-04-785980
    PubMed     Abstract available

  520. RAVANDI F
    How I treat Philadelphia chromosome positive acute lymphoblastic leukemia.
    Blood. 2018 Nov 15. pii: blood-2018-08-832105. doi: 10.1182/blood-2018-08-832105
    PubMed     Abstract available

  521. EDWARDS DK 5TH, Watanabe-Smith K, Rofelty A, Damnernsawad A, et al
    CSF1R inhibitors exhibit anti-tumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
    Blood. 2018 Nov 13. pii: blood-2018-03-838946. doi: 10.1182/blood-2018-03-838946
    PubMed     Abstract available

  522. LEBECQUE B, Lechevalier N
    B & B: basophils and bleeding, an atypical case of acute promyelocytic leukemia.
    Blood. 2018;132:2107.

  523. ABDUL-AZIZ AM, Sun Y, Hellmich C, Marlein CR, et al
    Acute myeloid leukemia induces pro-tumoral p16INK4a driven senescence in the bone marrow microenvironment.
    Blood. 2018 Nov 6. pii: blood-2018-04-845420. doi: 10.1182/blood-2018-04-845420.
    PubMed     Abstract available

    October 2018
  524. DINARDO CD, Pratz K, Pullarkat V, Jonas BA, et al
    Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    Blood. 2018 Oct 25. pii: blood-2018-08-868752. doi: 10.1182/blood-2018-08-868752
    PubMed     Abstract available

  525. BERTAINA A, Zecca M, Buldini B, Sacchi N, et al
    Unrelated donor vs HLA-haploidentical alpha/beta T-cell and B-cell depleted HSCT in children with acute leukemia.
    Blood. 2018 Oct 22. pii: blood-2018-07-861575. doi: 10.1182/blood-2018-07-861575
    PubMed     Abstract available

  526. ZHANG J, Zhang Y, Zhang M, Liu C, et al
    FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia.
    Blood. 2018 Oct 3. pii: blood-2018-04-845628. doi: 10.1182/blood-2018-04-845628.

  527. HERRMANN M, Krupka C, Deiser K, Brauchle B, et al
    Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Blood. 2018 Oct 1. pii: blood-2018-05-849802. doi: 10.1182/blood-2018-05-849802.
    PubMed     Abstract available

    September 2018
  528. CHEN LS, Bose P, Cruz ND, Jiang Y, et al
    A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
    Blood. 2018 Sep 25. pii: blood-2018-06-860593. doi: 10.1182/blood-2018-06-860593
    PubMed     Abstract available

  529. BALATTI V, Tomasello L, Rassenti LZ, Veneziano D, et al
    MiR-125a and MiR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients.
    Blood. 2018 Sep 21. pii: blood-2018-04-845115. doi: 10.1182/blood-2018-04-845115
    PubMed     Abstract available

  530. BOSMA M, Bartels M
    Hairy cell leukemia in a child?!
    Blood. 2018;132:1216.

  531. KATSURAGI T, Tsukada J
    Multiple subperiosteal bone resorption in adult T-cell leukemia/lymphoma.
    Blood. 2018;132:1086.

  532. BRETONES G, Alvarez MG, Arango JR, Rodriguez D, et al
    Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia.
    Blood. 2018 Sep 4. pii: blood-2017-09-804401. doi: 10.1182/blood-2017-09-804401.
    PubMed     Abstract available

    August 2018
  533. ALSADEQ A, Lenk L, Vadakumchery A, Cousins A, et al
    IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Aug 28. pii: blood-2018-04-844209. doi: 10.1182/blood-2018-04-844209

    Non-zero-sum game of transfusions: EOL in leukemia.
    Blood. 2018;132:676-678.

  535. ROGERS KA, Huang Y, Ruppert AS, Awan FT, et al
    Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
    Blood. 2018 Aug 15. pii: blood-2018-05-853564. doi: 10.1182/blood-2018-05-853564
    PubMed     Abstract available

  536. KIM T, Moon JH, Ahn JS, Kim YK, et al
    Next-generation sequencing based post-transplant monitoring of acute myeloid leukemia.
    Blood. 2018 Aug 14. pii: blood-2018-04-848028. doi: 10.1182/blood-2018-04-848028
    PubMed     Abstract available

  537. FERGUSON D, Kovach AE
    Rasburicase-induced hemolytic anemia in previously undiagnosed G6PD deficiency.
    Blood. 2018;132:673.

    July 2018
  538. PIKMAN Y, Stegmaier K
    Targeted therapy for fusion-driven high-risk acute leukemia.
    Blood. 2018 Jul 26. pii: blood-2018-04-784157. doi: 10.1182/blood-2018-04-784157
    PubMed     Abstract available

    Cuplike nuclear morphology in pediatric B-cell acute lymphoblastic leukemia.
    Blood. 2018;132:457.

  540. LI W, Chastain K
    NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia.
    Blood. 2018;132:456.

  541. Ambiguous lineage leukemia treatment.
    Blood. 2018;132:343.

  542. DREGER P, Ghia P, Schetelig J, van Gelder M, et al
    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.
    Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008
    PubMed     Abstract available

  543. SUD A, Chattopadhyay S, Thomsen H, Sundquist K, et al
    Familial risks of primary myeloid leukemia, myelodysplasia and myeloproliferative neoplasms.
    Blood. 2018 Jul 10. pii: blood-2018-06-858597. doi: 10.1182/blood-2018-06-858597

  544. THAKRAL B, Wang SA
    T-cell prolymphocytic leukemia negative for surface CD3 and CD45.
    Blood. 2018;132:111.

    June 2018
  545. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Blood. 2018 Jun 21. pii: blood-2018-02-835991. doi: 10.1182/blood-2018-02-835991

  546. O'DWYER K, Freyer DR, Horan JT
    Treatment strategies for adolescent and young adult patients with acute myeloid leukemia.
    Blood. 2018 Jun 12. pii: blood-2017-12-778472. doi: 10.1182/blood-2017-12-778472
    PubMed     Abstract available

  547. BOISSEL N, Baruchel A
    Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?
    Blood. 2018 Jun 12. pii: blood-2018-02-778530. doi: 10.1182/blood-2018-02-778530
    PubMed     Abstract available

  548. ROBERTS KG, Janke LJ, Zhao Y, Seth A, et al
    ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
    Blood. 2018 Jun 7. pii: blood-2018-05-849554. doi: 10.1182/blood-2018-05-849554.

    May 2018
  549. ALDOSS I, Song JY
    Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab.
    Blood. 2018;131:2507.

  550. LEBLANC TW, Egan PC, Olszewski AJ
    Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.
    Blood. 2018 May 30. pii: blood-2018-03-842575. doi: 10.1182/blood-2018-03-842575
    PubMed     Abstract available

  551. MELO-CARDENAS J, Xu Y, Wei J, Tan C, et al
    USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1 dependent mechanism.
    Blood. 2018 May 29. pii: blood-2017-10-811760. doi: 10.1182/blood-2017-10-811760
    PubMed     Abstract available

  552. PATEL SS, Dorfman DM
    Leukemic-phase progression of aleukemic mast cell leukemia.
    Blood. 2018;131:2406.

  553. TESTI AM, Pession A, Diverio D, Grimwade D, et al
    Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL.
    Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528
    PubMed     Abstract available

  554. MAIFREDE S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al
    Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Blood. 2018 May 21. pii: blood-2018-02-834895. doi: 10.1182/blood-2018-02-834895
    PubMed     Abstract available

  555. CLOT G, Jares P, Gine E, Navarro A, et al
    A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma.
    Blood. 2018 May 16. pii: blood-2018-03-838136. doi: 10.1182/blood-2018-03-838136
    PubMed     Abstract available

  556. LUO H, Wang F, Zha J, Li H, et al
    CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
    Blood. 2018 May 14. pii: blood-2017-11-814319. doi: 10.1182/blood-2017-11-814319
    PubMed     Abstract available

  557. OLAIYA OO, Li W
    Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia.
    Blood. 2018;131:2178.

  558. ROBINSON HR, Qi J, Cook EM, Nichols C, et al
    A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Blood. 2018 May 9. pii: blood-2018-02-830992. doi: 10.1182/blood-2018-02-830992.
    PubMed     Abstract available

  559. TOPP MS, Zimmerman Z, Cannell P, Dombret H, et al
    Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Blood. 2018 May 8. pii: blood-2017-09-804658. doi: 10.1182/blood-2017-09-804658.
    PubMed     Abstract available

  560. ZHU HH, Liu YR
    Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia.
    Blood. 2018 May 4. pii: blood-2018-02-834051. doi: 10.1182/blood-2018-02-834051.

  561. STEIN EM, Garcia-Manero G, Rizzieri DA, Tibes R, et al
    The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
    Blood. 2018 May 3. pii: blood-2017-12-818948. doi: 10.1182/blood-2017-12-818948.
    PubMed     Abstract available

  562. HRUSAK O, De Haas V, Stancikova J, Vakrmanova B, et al
    International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
    Blood. 2018 May 2. pii: blood-2017-12-821363. doi: 10.1182/blood-2017-12-821363.
    PubMed     Abstract available

    April 2018
  563. LI S, Xu J
    Plasma cell leukemia presenting as "lymphocytosis".
    Blood. 2018;131:1994.

  564. YANG J, LeBlanc FR, Dighe SA, Hamele CE, et al
    TRAIL mediates and sustains constitutive NF-kappaB activation in LGL leukemia.
    Blood. 2018 Apr 26. pii: blood-2017-09-808816. doi: 10.1182/blood-2017-09-808816
    PubMed     Abstract available

  565. MCKENNA MK, Noothi SK, Alhakeem SS, Oben KZ, et al
    Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
    Blood. 2018 Apr 25. pii: blood-2017-10-813931. doi: 10.1182/blood-2017-10-813931
    PubMed     Abstract available

  566. ITZYKSON R, Duployez N, Fasan A, Decool G, et al
    Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.
    Blood. 2018 Apr 24. pii: blood-2018-03-837781. doi: 10.1182/blood-2018-03-837781
    PubMed     Abstract available

  567. HASAN MK, Yu J, Widhopf GF 2nd, Rassenti LZ, et al
    Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Blood. 2018 Apr 20. pii: blood-2017-12-819383. doi: 10.1182/blood-2017-12-819383
    PubMed     Abstract available

  568. KLEINSTERN G, Camp NJ, Goldin LR, Vachon CM, et al
    Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
    Blood. 2018 Apr 19. pii: blood-2017-11-814608. doi: 10.1182/blood-2017-11-814608
    PubMed     Abstract available

  569. HEERY DM
    A fellowship of Ring1 maintains AML stem cells.
    Blood. 2018;131:1771-1773.

  570. LAETSCH TW, Maude SL, Milone MC, Davis KL, et al
    False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
    Blood. 2018 Apr 18. pii: blood-2017-12-822940. doi: 10.1182/blood-2017-12-822940

  571. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Abstract available

  572. RANK CU, Toft N, Tuckuviene R, Grell K, et al
    Thromboembolism in Acute Lymphoblastic Leukemia: Results of NOPHO ALL2008 Protocol Treatment in Patients 1-45 Years.
    Blood. 2018 Apr 16. pii: blood-2018-01-827949. doi: 10.1182/blood-2018-01-827949
    PubMed     Abstract available

  573. JIANG X, Zhou D
    ALK(+) small cell variant of anaplastic large cell lymphoma with leukemic presentation.
    Blood. 2018;131:1764.

  574. WANG F, Demir S, Gehringer F, Osswald CD, et al
    Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Apr 5. pii: blood-2017-10-813576. doi: 10.1182/blood-2017-10-813576.
    PubMed     Abstract available

  575. KRAUSE DS
    Et tu, E2F1? The assassins of CML stem cells.
    Blood. 2018;131:1499-1500.

  576. STATLER A, Othus M, Erba HP, Chauncey TR, et al
    Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
    Blood. 2018 Apr 4. pii: blood-2018-01-826693. doi: 10.1182/blood-2018-01-826693.
    PubMed     Abstract available

    March 2018
  577. CORTES JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, et al
    Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086
    PubMed     Abstract available

  578. PAIETTA E
    Consensus on MRD in AML?
    Blood. 2018;131:1265-1266.

  579. SCHUURHUIS GJ, Heuser M, Freeman S, Bene MC, et al
    Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
    Blood. 2018;131:1275-1291.
    PubMed     Abstract available

  580. WOOD B, Wu D, Crossley B, Dai Y, et al
    Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
    Blood. 2018;131:1350-1359.
    PubMed     Abstract available

  581. RUIZ S, Chen YH
    Acute myeloid leukemia with coexistence of t(9;22) and inv(16).
    Blood. 2018;131:1263.

  582. HALLEK M, Cheson BD, Catovsky D, Caligaris-Cappio F, et al
    Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.
    Blood. 2018 Mar 14. pii: blood-2017-09-806398. doi: 10.1182/blood-2017-09-806398
    PubMed     Abstract available

  583. YAMATO G, Shiba N, Yoshida K, Hara Y, et al
    RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis.
    Blood. 2018 Mar 14. pii: blood-2017-11-814442. doi: 10.1182/blood-2017-11-814442

  584. SMITH M, Zakrzewski J, James S, Sadelain M, et al
    Posttransplant chimeric antigen receptor therapy.
    Blood. 2018;131:1045-1052.
    PubMed     Abstract available

  585. SOIFFER RJ, Davids MS, Chen YB
    Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation.
    Blood. 2018;131:1073-1080.
    PubMed     Abstract available

  586. ZAMMARCHI F, Corbett S, Adams L, Tyrer PC, et al
    ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
    Blood. 2018;131:1094-1105.
    PubMed     Abstract available

  587. SHOMALI W, Gotlib J
    Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.
    Blood. 2018;131:1036.

  588. WYNNE J, Stock W
    "Dar"-ing to target CD38 in T-ALL.
    Blood. 2018;131:948-949.

    MRD negativity as a surrogate for PFS in CLL?
    Blood. 2018;131:943-944.

  590. DIMIER N, Delmar P, Ward C, Morariu-Zamfir R, et al
    A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
    Blood. 2018;131:955-962.
    PubMed     Abstract available

    February 2018
  591. KREITMAN RJ, Tallman MS, Robak T, Coutre S, et al
    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up.
    Blood. 2018 Feb 27. pii: blood-2017-09-803072. doi: 10.1182/blood-2017-09-803072
    PubMed     Abstract available

  592. DUARTE D, Hawkins ED, Lo Celso C
    The interplay of leukemia cells and the bone marrow microenvironment.
    Blood. 2018 Feb 27. pii: blood-2017-12-784132. doi: 10.1182/blood-2017-12-784132
    PubMed     Abstract available

  593. LIU T, Wen L, Yuan H, Wang Y, et al
    Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Blood. 2018 Feb 27. pii: blood-2017-11-818716. doi: 10.1182/blood-2017-11-818716

  594. SCHLIFFKE S, Buhs S, Bolz S, Gerull H, et al
    The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
    Blood. 2018 Feb 23. pii: blood-2017-06-788166. doi: 10.1182/blood-2017-06-788166

  595. JAITLY V, Wang W
    B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
    Blood. 2018;131:941.

  596. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.

  597. GALLIPOLI P, Giotopoulos G, Tzelepis K, Costa ASH, et al
    Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
    Blood. 2018 Feb 20. pii: blood-2017-12-820035. doi: 10.1182/blood-2017-12-820035
    PubMed     Abstract available

  598. SCHAFER D, Olsen M, Lahnemann D, Stanulla M, et al
    Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening.
    Blood. 2018;131:821-826.

  599. CARAFFINI V, Perfler B, Berg JL, Uhl B, et al
    Loss of RKIP is a frequent event in myeloid sarcoma and promotes leukemic tissue infiltration.
    Blood. 2018;131:826-830.

  600. WIERZ M, Pierson S, Guyonnet L, Viry E, et al
    Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
    Blood. 2018 Feb 13. pii: blood-2017-06-792267. doi: 10.1182/blood-2017-06-792267

  601. BHAGWAT AS, Lu B, Vakoc CR
    Enhancer dysfunction in leukemia.
    Blood. 2018 Feb 9. pii: blood-2017-11-737379. doi: 10.1182/blood-2017-11-737379.
    PubMed     Abstract available

  602. NAKADA D
    ENLightening YEATS in antagonizing polycomb repression.
    Blood. 2018;131:591.

  603. HETZNER K, Garcia-Cuellar MP, Buttner C, Slany RK, et al
    The interaction of ENL with PAF1 mitigates polycomb silencing and facilitates murine leukemogenesis.
    Blood. 2018;131:662-673.
    PubMed     Abstract available

  604. VOISSET E, Moravcsik E, Stratford EW, Jaye A, et al
    Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.
    Blood. 2018;131:636-648.
    PubMed     Abstract available

  605. GREEN DJ, O'Steen S, Lin Y, Comstock ML, et al
    CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
    Blood. 2018;131:611-620.
    PubMed     Abstract available

  606. ZHANG Y, Gao Y, Zhang H, Zhang J, et al
    PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
    Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510.
    PubMed     Abstract available

  607. YUN S, Zhang L, Patel MR, Knepper TC, et al
    Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL).
    Blood. 2018 Feb 5. pii: blood-2017-11-819276. doi: 10.1182/blood-2017-11-819276.

  608. MURAKAMI N, Okuno Y, Yoshida K, Shiraishi Y, et al
    Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Blood. 2018 Feb 2. pii: blood-2017-07-798157. doi: 10.1182/blood-2017-07-798157.
    PubMed     Abstract available

  609. O'BRIEN S, Furman RR, Coutre S, Flinn IW, et al
    Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
    Blood. 2018 Feb 2. pii: blood-2017-10-810044. doi: 10.1182/blood-2017-10-810044.
    PubMed     Abstract available

  610. LAZAREVIC V, Orsmark-Pietras C, Lilljebjorn H, Pettersson L, et al
    Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.
    Blood. 2018;131:577-581.

    January 2018
  611. DINMOHAMED AG, Posthuma EFM, Visser O, Kater AP, et al
    Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands.
    Blood. 2018 Jan 30. pii: blood-2017-12-820381. doi: 10.1182/blood-2017-12-820381

  612. SHIMA H, Takamatsu-Ichihara E, Shino M, Yamagata K, et al
    Ring1A and Ring 1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells.
    Blood. 2018 Jan 25. pii: blood-2017-05-787226. doi: 10.1182/blood-2017-05-787226
    PubMed     Abstract available

  613. TAKAHASHI K, Hu B, Wang F, Yan Y, et al
    Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
    Blood. 2018 Jan 22. pii: blood-2017-11-817296. doi: 10.1182/blood-2017-11-817296
    PubMed     Abstract available

  614. GOKBUGET N, Dombret H, Bonifacio M, Reichle A, et al
    Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-798322. doi: 10.1182/blood-2017-08-798322
    PubMed     Abstract available

  615. HANDGRETINGER R, Schilbach K
    The potential role of gammadelta T cells after allogeneic HCT for leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-752162. doi: 10.1182/blood-2017-08-752162
    PubMed     Abstract available

  616. COOLEY S, Parham P, Miller JS
    Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation.
    Blood. 2018 Jan 22. pii: blood-2017-08-752170. doi: 10.1182/blood-2017-08-752170
    PubMed     Abstract available

  617. GUTJAHR JC, Szenes E, Tschech L, Asslaber D, et al
    Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Blood. 2018 Jan 19. pii: blood-2017-08-802462. doi: 10.1182/blood-2017-08-802462
    PubMed     Abstract available

  618. PFEIFER H, Raum K, Markovic S, Nowak V, et al
    Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.
    Blood. 2018 Jan 18. pii: blood-2017-07-796862. doi: 10.1182/blood-2017-07-796862
    PubMed     Abstract available

  619. SUN W, Triche T Jr., Malvar J, Gaynon P, et al
    A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium.
    Blood. 2018 Jan 16. pii: blood-2017-09-803809. doi: 10.1182/blood-2017-09-803809
    PubMed     Abstract available

  620. JANOVSKA P, Verner J, Kohoutek J, Bryjova L, et al
    Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia.
    Blood. 2018 Jan 9. pii: blood-2017-05-786947. doi: 10.1182/blood-2017-05-786947.
    PubMed     Abstract available

  621. BRIDE KL, Vincent TL, Im SY, Aplenc R, et al
    Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).
    Blood. 2018 Jan 5. pii: blood-2017-07-794214. doi: 10.1182/blood-2017-07-794214.
    PubMed     Abstract available

  622. COUTRE S, Choi M, Furman RR, Eradat H, et al
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Blood. 2018 Jan 5. pii: blood-2017-06-788133. doi: 10.1182/blood-2017-06-788133.
    PubMed     Abstract available

  623. LOCKE FL, Anasetti C
    Off-the-shelf TCR for graft-versus-leukemia without GVHD.
    Blood. 2018;131:5-7.

  624. MILNE TA
    LEDGF: a leukemia-specific target.
    Blood. 2018;131:4-5.

    AML: exposed and exploited?
    Blood. 2018;131:8-10.

  626. EL ASHKAR S, Schwaller J, Pieters T, Goossens S, et al
    LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis.
    Blood. 2018;131:95-107.
    PubMed     Abstract available

  627. HILL JA, Li D, Hay KA, Green ML, et al
    Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Blood. 2018;131:121-130.
    PubMed     Abstract available

    December 2017
  628. GROCKOWIAK E, Laperrousaz B, Jeanpierre S, Voeltzel T, et al
    Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
    Blood. 2017;130:2860-2871.
    PubMed     Abstract available

  629. SHIOZAWA Y, Malcovati L, Galli A, Pellagatti A, et al
    Gene expression and risk of leukemic transformation in myelodysplasia.
    Blood. 2017;130:2642-2653.
    PubMed     Abstract available

  630. PRATS-MARTIN C, Morales-Camacho RM
    Circulating hypergranular neoplastic cells: not always leukemic promyelocytes.
    Blood. 2017;130:2689.

  631. YAO L, Wen L, Wang N, Liu T, et al
    Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA.
    Blood. 2017 Dec 13. pii: blood-2017-09-807370. doi: 10.1182/blood-2017-09-807370

  632. RAIKAR SS, Park SI, Leong T, Jaye DL, et al
    Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival.
    Blood. 2017 Dec 9. pii: blood-2017-09-807602. doi: 10.1182/blood-2017-09-807602.

  633. WEI AH, Tiong IS
    Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Blood. 2017;130:2469-2474.
    PubMed     Abstract available

  634. BOSE P, Konopleva MY
    T-PLL: another check on the venetoclax list?
    Blood. 2017;130:2447-2448.

  635. OBSTFELD AE, Frey NV, Mansfield K, Lacey SF, et al
    Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
    Blood. 2017;130:2569-2572.

  636. STEIN EM, Walter RB, Erba HP, Fathi AT, et al
    A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33 positive acute myeloid leukemia (AML).
    Blood. 2017 Dec 1. pii: blood-2017-06-789800. doi: 10.1182/blood-2017-06-789800.
    PubMed     Abstract available

    November 2017
  637. COOPER JN, Young NS
    Clonality in context: hematopoietic clones in their marrow environment.
    Blood. 2017;130:2363-2372.
    PubMed     Abstract available

  638. ZHEN T, Kwon EM, Zhao L, Hsu J, et al
    Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.
    Blood. 2017;130:2431-2442.
    PubMed     Abstract available

  639. RASHIDI A, Gilles S
    The unused iron.
    Blood. 2017;130:2445.

  640. STRAUBE J, Ling VY, Hill GR, Lane SW, et al
    The impact of age, NPM1(mut) and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia.
    Blood. 2017 Nov 28. pii: blood-2017-09-807438. doi: 10.1182/blood-2017-09-807438

  641. JOHNSRUD AJ, Pina-Oviedo S
    Carcinocythemia (carcinoma cell leukemia).
    Blood. 2017;130:2357.

    FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.
    Blood. 2017;130:2278-2282.
    PubMed     Abstract available

  643. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.

  644. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.

  645. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.

  646. HU Z, Konoplev S
    Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia.
    Blood. 2017;130:2150.

  647. ISSA GC, Kantarjian HM, Gonzalez GN, Borthakur G, et al
    Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
    Blood. 2017;130:2084-2091.
    PubMed     Abstract available

    Prognostic relevance of CCAs/Ph(-) in CML settled.
    Blood. 2017;130:2046-2047.

  649. LOCATELLI F, Valsecchi MG, Moricke A, Zimmermann M, et al
    Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
    Blood. 2017;130:2146-2149.

  650. SERAFIN V, Capuzzo G, Milani G, Minuzzo SA, et al
    Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Blood. 2017 Nov 3. pii: blood-2017-05-784603. doi: 10.1182/blood-2017-05-784603.
    PubMed     Abstract available

  651. TAWARA I, Kageyama S, Miyahara Y, Fujiwara H, et al
    Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
    Blood. 2017;130:1985-1994.
    PubMed     Abstract available

    October 2017
  652. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI): a systematic review and meta-analysis.
    Blood. 2017 Oct 30. pii: blood-2017-09-806034. doi: 10.1182/blood-2017-09-806034

  653. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Abstract available

  654. FALINI B, Sportoletti P
    A scale of "bad" co-mutations in NPM1-driven AML.
    Blood. 2017;130:1877-1879.

  655. BOUVIER S, Martin M
    Atypical monoblasts with micronuclei.
    Blood. 2017;130:1958.

  656. GILLISSEN MA, Kedde M, de Jong G, Moiset G, et al
    AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses.
    Blood. 2017 Oct 23. pii: blood-2017-02-768762. doi: 10.1182/blood-2017-02-768762
    PubMed     Abstract available

  657. DOSSA RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, et al
    Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
    Blood. 2017 Oct 19. pii: blood-2017-07-791608. doi: 10.1182/blood-2017-07-791608
    PubMed     Abstract available

  658. PETIT A, Trinquand A, Chevret S, Ballerini P, et al
    Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-04-778829. doi: 10.1182/blood-2017-04-778829
    PubMed     Abstract available

  659. TIAO G, Improgo MR, Tausch E, Fernandes SM, et al
    Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-08-800128. doi: 10.1182/blood-2017-08-800128

  660. HARANKHEDKAR S, Gupta R
    MPO-negative inclusions and Auer rod-like structures in a case of acute myeloid leukemia with t(8;21).
    Blood. 2017;130:1869.

  661. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.

  662. ODA SK, Daman AW, Garcia NM, Wagener F, et al
    A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.
    Blood. 2017 Oct 17. pii: blood-2017-04-777052. doi: 10.1182/blood-2017-04-777052
    PubMed     Abstract available

  663. SANDA T
    RUNX1 in T-ALL: tumor suppressive or oncogenic?
    Blood. 2017;130:1686-1688.

  664. XU Z
    AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis.
    Blood. 2017;130:1775.

  665. APPELBAUM FR, Bernstein ID
    Gemtuzumab ozogamicin for acute myeloid leukemia.
    Blood. 2017 Oct 11. pii: blood-2017-09-797712. doi: 10.1182/blood-2017-09-797712
    PubMed     Abstract available

  666. MAR BG, Chu SH, Kahn JD, Krivstov AV, et al
    SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
    Blood. 2017 Oct 10. pii: blood-2017-03-775569. doi: 10.1182/blood-2017-03-775569
    PubMed     Abstract available

  667. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017;130:1620-1627.
    PubMed     Abstract available

  668. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Abstract available

  669. MARLEIN CR, Zaitseva L, Piddock RE, Robinson SD, et al
    NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts.
    Blood. 2017;130:1649-1660.
    PubMed     Abstract available

  670. WONG RWJ, Ngoc PCT, Leong WZ, Yam AWY, et al
    Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Blood. 2017 Oct 4. pii: blood-2017-06-792184. doi: 10.1182/blood-2017-06-792184.
    PubMed     Abstract available

  671. TASIAN SK, Loh ML, Hunger SP
    Philadelphia chromosome-like acute lymphoblastic leukemia.
    Blood. 2017 Oct 2. pii: blood-2017-06-743252. doi: 10.1182/blood-2017-06-743252.
    PubMed     Abstract available

    September 2017
  672. THAKRAL B, Wang SA
    "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
    Blood. 2017;130:1600.

  673. KARAESMEN E, Rizvi AA, Preus LM, McCarthy PL, et al
    Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
    Blood. 2017;130:1585-1596.
    PubMed     Abstract available

  674. JABBOUR E, Short NJ, Montalban-Bravo G, Huang X, et al
    Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Blood. 2017;130:1514-1522.
    PubMed     Abstract available

  675. ADVANI AS
    "MOR" engineering of antibodies in ALL.
    Blood. 2017;130:1487-1488.

  676. BOIDOL B, Kornauth C, van der Kouwe E, Prutsch N, et al
    First in human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Blood. 2017 Sep 27. pii: blood-2017-05-785683. doi: 10.1182/blood-2017-05-785683
    PubMed     Abstract available

  677. MUELLER KT, Maude SL, Porter DL, Frey N, et al
    Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
    Blood. 2017 Sep 21. pii: blood-2017-06-786129. doi: 10.1182/blood-2017-06-786129
    PubMed     Abstract available

  678. SHEA TC
    Are outcomes of allografts for CLL still relevant?
    Blood. 2017;130:1393-1394.

  679. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.

  680. KRAMER I, Stilgenbauer S, Dietrich S, Bottcher S, et al
    Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
    Blood. 2017;130:1477-1480.

  681. ZURLI V, Wimmer G, Cattaneo F, Candi V, et al
    Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
    Blood. 2017 Sep 20. pii: blood-2017-03-775858. doi: 10.1182/blood-2017-03-775858
    PubMed     Abstract available

  682. WANG HY, Feldman AL
    Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia.
    Blood. 2017;130:1387.

  683. LIN S, Ptasinska A, Chen X, Shrestha M, et al
    A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Blood. 2017;130:1213-1222.
    PubMed     Abstract available

  684. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.

  685. AHCI M, Toffalori C, Bouwmans E, Crivello P, et al
    A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.
    Blood. 2017;130:1270-1273.

    August 2017
    CDK9 inhibition for ATL therapy.
    Blood. 2017;130:1074-1075.

  687. LEHNERTZ B, Zhang YW, Boivin I, Mayotte N, et al
    H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations.
    Blood. 2017 Aug 30. pii: blood-2017-03-774653. doi: 10.1182/blood-2017-03-774653
    PubMed     Abstract available

  688. DOVEY OM, Cooper JL, Mupo A, Grove CS, et al
    Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.
    Blood. 2017 Aug 23. pii: blood-2017-01-760595. doi: 10.1182/blood-2017-01-760595
    PubMed     Abstract available

  689. BRUNSON A, Keegan THM, Bang H, Mahajan A, et al
    Increased risk of leukemia among sickle cell disease patients in California.
    Blood. 2017 Aug 22. pii: blood-2017-05-783233. doi: 10.1182/blood-2017-05-783233

  690. ANGUILLE S, Van de Velde AL, Smits EL, Van Tendeloo VF, et al
    Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia.
    Blood. 2017 Aug 22. pii: blood-2017-04-780155. doi: 10.1182/blood-2017-04-780155
    PubMed     Abstract available

  691. NAGEL I, Bartels M, Duell J, Oberg HH, et al
    Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.
    Blood. 2017 Aug 21. pii: blood-2017-05-782888. doi: 10.1182/blood-2017-05-782888
    PubMed     Abstract available

  692. ZHOU XY, Behdad A
    Relapse of an acute leukemia of mixed lineage as an isolated orbital mass.
    Blood. 2017;130:953.

  693. KATAYAMA S, Suzuki M, Yamaoka A, Keleku-Lukwete N, et al
    GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Blood. 2017;130:908-919.
    PubMed     Abstract available

  694. MAGINA KN, Pregartner G, Zebisch A, Wolfler A, et al
    Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Blood. 2017;130:946-948.

  695. DURHAM BH, Getta B, Dietrich S, Taylor J, et al
    Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
    Blood. 2017 Aug 11. pii: blood-2017-01-765107. doi: 10.1182/blood-2017-01-765107
    PubMed     Abstract available

  696. KARJALAINEN R, Pemovska T, Popa M, Liu M, et al
    JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Blood. 2017;130:789-802.
    PubMed     Abstract available

    Hitting the target in IDH2 mutant AML.
    Blood. 2017;130:693-694.

  698. SELIMOGLU-BUET D, Badaoui B, Benayoun E, Toma A, et al
    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
    Blood. 2017;130:832-835.

  699. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017 Aug 9. pii: blood-2017-02-749101. doi: 10.1182/blood-2017-02-749101.
    PubMed     Abstract available

  700. CHOI A, Illendula A, Pulikkan JA, Roderick JE, et al
    RUNX1 is required for oncogenic Myb and Myc enhancer activity in T cell acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-03-775536. doi: 10.1182/blood-2017-03-775536.
    PubMed     Abstract available

  701. LAFAGE-POCHITALOFF M, Baranger L, Hunault M, Cuccuini W, et al
    Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-05-783852. doi: 10.1182/blood-2017-05-783852.
    PubMed     Abstract available

  702. MIZUKAWA B, O'Brien E, Moreira DC, Wunderlich M, et al
    Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
    Blood. 2017 Aug 4. pii: blood-2016-12-758458. doi: 10.1182/blood-2016-12-758458.
    PubMed     Abstract available

  703. LILLJEBJORN H, Fioretos T
    New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 4. pii: blood-2017-05-742643. doi: 10.1182/blood-2017-05-742643.
    PubMed     Abstract available

  704. ARRANTO C, Tzankov A
    Broken heart by T-prolymphocytic leukemia.
    Blood. 2017;130:691.

  705. IZRAELI S, Eckert C
    Targeted therapy of CNS leukemia?
    Blood. 2017;130:562-563.

  706. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Abstract available

    July 2017
  707. WALLACE JA, O'Connell RM
    MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.
    Blood. 2017 Jul 27. pii: blood-2016-10-697698. doi: 10.1182/blood-2016-10-697698
    PubMed     Abstract available

  708. GODLEY LA, Shimamura A
    Genetic predisposition to hematologic malignancies: management and surveillance.
    Blood. 2017;130:424-432.
    PubMed     Abstract available

  709. YOSHIMI A, Balasis ME, Vedder A, Feldman K, et al
    Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Blood. 2017;130:397-407.
    PubMed     Abstract available

  710. RAU RE
    CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3.
    Blood. 2017;130:385-386.

  711. DONG L, Zheng H, Qu CK
    CCL3 is a key mediator for the leukemogenic effect of Ptpn11 activating mutations in the stem cell microenvironment.
    Blood. 2017 Jul 27. pii: blood-2017-06-791103. doi: 10.1182/blood-2017-06-791103

  712. TOBOSO DG, Campos CB
    Peripheral eosinophilia as the first manifestation of B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32).
    Blood. 2017;130:380.

  713. GOMES-SILVA D, Srinivasan M, Sharma S, Lee CM, et al
    CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Blood. 2017;130:285-296.
    PubMed     Abstract available

  714. AL SAYED MF, Ruckstuhl CA, Hilmenyuk T, Claus C, et al
    CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Blood. 2017;130:297-309.
    PubMed     Abstract available

  715. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood. 2017;130:232.

  716. THAKRAL B, Muzzafar T
    Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Blood. 2017;130:231.

  717. TALSMA CE, Boyer DF
    Myeloid leukemia associated with Down syndrome.
    Blood. 2017;130:230.

  718. AGATHANGGELOU A, Smith E, Davies NJ, Kwok M, et al
    USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Blood. 2017;130:156-166.
    PubMed     Abstract available

  719. SAMPATH D
    Targeting deubiquitinases in CLL.
    Blood. 2017;130:100-101.

  720. PILLAI V, Maude SL
    CART attack.
    Blood. 2017;130:229.

  721. SCHEWE DM, Alsadeq A, Sattler C, Lenk L, et al
    An Fc engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
    Blood. 2017 Jul 11. pii: blood-2017-01-764316. doi: 10.1182/blood-2017-01-764316
    PubMed     Abstract available

  722. CARPENTER PA, Johnston L, Fernandez HF, Radich JP, et al
    Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.
    Blood. 2017 Jul 11. pii: blood-2017-03-771121. doi: 10.1182/blood-2017-03-771121

  723. BLACKBURN NB, Marthick JR, Banks A, Charlesworth JC, et al
    Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.
    Blood. 2017;130:86-88.

  724. KITAMURA N, Nakanishi T, Yoshida Y, Higashi T, et al
    HTLV-I-associated posttransplant lymphoproliferative disorder following virus transmission from recipient to donor cells.
    Blood. 2017;130:84-86.

    June 2017
  725. QUESADA AE, Kanagal-Shamanna R
    Targeted therapy-induced differentiation of acute myeloid leukemia blasts.
    Blood. 2017;129:3503.

  726. LEVIS M
    Midostaurin approved for FLT3-mutated AML.
    Blood. 2017;129:3403-3406.
    PubMed     Abstract available

  727. CHAUDHRY P, Singh M, Triche TJ, Guzman M, et al
    GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.
    Blood. 2017;129:3465-3475.
    PubMed     Abstract available

  728. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.

  729. RIGOLIN GM, Cavallari M, Quaglia FM, Formigaro L, et al
    In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
    Blood. 2017;129:3495-3498.

  730. MORIYAMA T, Yang YL, Nishii R, Ariffin H, et al
    Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.
    Blood. 2017 Jun 28. pii: blood-2017-05-782383. doi: 10.1182/blood-2017-05-782383
    PubMed     Abstract available

  731. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Abstract available

  732. BRIERLEY CK, Eyre TA
    Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
    Blood. 2017;129:3396.

  733. ANDERSON MA, Tam C, Lew TE, Juneja S, et al
    Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
    Blood. 2017;129:3362-3370.
    PubMed     Abstract available

  734. MALCOVATI L, Galli A, Travaglino E, Ambaglio I, et al
    Clinical significance of somatic mutation in unexplained blood cytopenia.
    Blood. 2017;129:3371-3378.
    PubMed     Abstract available

  735. RESHMI SC, Harvey RC, Roberts KG, Stonerock E, et al
    Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Blood. 2017;129:3352-3361.
    PubMed     Abstract available

  736. TOMIZAWA D, Kolb EA
    Down syndrome and AML: where do we go from here?
    Blood. 2017;129:3274-3275.

  737. SHAND JC
    Looking up for AML in Down syndrome.
    Blood. 2017;129:3273-3274.

    Restoring leukemia cell function from the inside out.
    Blood. 2017;129:3137-3138.

  739. GOOSSENS S, Van Vlierberghe P
    Novel oncogenic noncoding mutations in T-ALL.
    Blood. 2017;129:3140-3142.

  740. GARRISON BS, Rybak AP, Beerman I, Heesters B, et al
    ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
    Blood. 2017 Jun 14. pii: blood-2016-09-738591. doi: 10.1182/blood-2016-09-738591
    PubMed     Abstract available

  741. PROKOCIMER M, Molchadsky A, Rotter V
    Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy.
    Blood. 2017 Jun 12. pii: blood-2017-02-763086. doi: 10.1182/blood-2017-02-763086
    PubMed     Abstract available

  742. PRIETO D, Sotelo N, Seija N, Sernbo S, et al
    S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-kappaB activity during disease progression.
    Blood. 2017 Jun 8. pii: blood-2017-02-769851. doi: 10.1182/blood-2017-02-769851.
    PubMed     Abstract available

  743. WALLACE JA, Kagele DA, Eiring AM, Kim CN, et al
    miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Blood. 2017;129:3074-3086.
    PubMed     Abstract available

  744. RASHIDI A, Courville EL
    Double-heart sign.
    Blood. 2017;129:3134.

  745. KATO I, Nishinaka Y, Nakamura M, Akarca AU, et al
    Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.
    Blood. 2017;129:3126-3129.

  746. STEIN EM, DiNardo CD, Pollyea DA, Fathi AT, et al
    Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.
    Blood. 2017 Jun 6. pii: blood-2017-04-779405. doi: 10.1182/blood-2017-04-779405.
    PubMed     Abstract available

  747. AMATANGELO MD, Quek L, Shih A, Stein EM, et al
    Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Blood. 2017 Jun 6. pii: blood-2017-04-779447. doi: 10.1182/blood-2017-04-779447.
    PubMed     Abstract available

  748. LOCATELLI F, Merli P, Pagliara D, Li Pira G, et al
    Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion.
    Blood. 2017 Jun 6. pii: blood-2017-04-779769. doi: 10.1182/blood-2017-04-779769.
    PubMed     Abstract available

  749. CHELONI G, Tanturli M, Tusa I, DeSouza NH, et al
    Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
    Blood. 2017 Jun 2. pii: blood-2016-10-745588. doi: 10.1182/blood-2016-10-745588.
    PubMed     Abstract available

  750. SOLARY E, Itzykson R
    How I treat chronic myelomonocytic leukemia.
    Blood. 2017 Jun 1. pii: blood-2017-04-736421. doi: 10.1182/blood-2017-04-736421.
    PubMed     Abstract available

    May 2017
  751. MUNCH V, Trentin L, Herzig J, Demir S, et al
    Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor.
    Blood. 2017 May 26. pii: blood-2017-03-769315. doi: 10.1182/blood-2017-03-769315
    PubMed     Abstract available

  752. MAN N, Tan Y, Sun XJ, Liu F, et al
    Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
    Blood. 2017;129:2782-2792.
    PubMed     Abstract available

  753. HOVORKOVA L, Zaliova M, Venn NC, Bleckmann K, et al
    Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
    Blood. 2017;129:2771-2781.
    PubMed     Abstract available

  754. HUNGER SP
    CML in blast crisis: more common than we think?
    Blood. 2017;129:2713-2714.

  755. WALTER HS, Jayne S, Rule SA, Cartron G, et al
    Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
    Blood. 2017;129:2808-2810.

  756. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Abstract available

  757. CHEN TL, Tran M, Lakshmanan A, Harrington BK, et al
    NF-kappaB p50 (nfkb1) contributes to pathogenesis in the Emu-TCL1 mouse model of chronic lymphocytic leukemia.
    Blood. 2017 May 17. pii: blood-2017-01-761130. doi: 10.1182/blood-2017-01-761130

  758. BARR PM, Brown JR, Hillmen P, O'Brien S, et al
    Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Blood. 2017;129:2612-2615.
    PubMed     Abstract available

  759. VALGARDSDOTTIR R, Cattaneo I, Klein C, Introna M, et al
    Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
    Blood. 2017;129:2636-2644.
    PubMed     Abstract available

  760. LIYANAGE SU, Hurren R, Voisin V, Bridon G, et al
    Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
    Blood. 2017;129:2657-2666.
    PubMed     Abstract available

  761. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.

  762. PINTON P
    A mitochondrial drug to treat AML.
    Blood. 2017;129:2597-2599.

  763. SMITH CC, Paguirigan A, Jeschke GR, Lin KC, et al
    Heterogeneous resistance to quizartinib in acute myeloid leukemia (AML) revealed by single cell analysis.
    Blood. 2017 May 10. pii: blood-2016-04-711820. doi: 10.1182/blood-2016-04-711820
    PubMed     Abstract available

  764. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.

  765. DOURADO KMC, Baik J, Oliveira VKP, Beltrame M, et al
    Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
    Blood. 2017;129:2526-2536.
    PubMed     Abstract available

  766. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.

  767. LAMPSON BL, Yu L, Glynn RJ, Barrientos JC, et al
    Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Blood. 2017;129:2581-2584.

  768. GORINI F, Azzimonti L, Delfanti G, Scarfo L, et al
    Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
    Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
    PubMed     Abstract available

    April 2017
  769. PARILLA M, Venkataraman G
    The thin line between CML and CMML.
    Blood. 2017;129:2456.

  770. RADICH J
    Understanding CML, 1 cell at a time.
    Blood. 2017;129:2339-2340.

  771. KRUTH K, Fang M, Shelton DN, Abu-Halawa O, et al
    Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Blood. 2017 Apr 19. pii: blood-2017-02-766204. doi: 10.1182/blood-2017-02-766204
    PubMed     Abstract available

  772. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Abstract available

  773. VUJKOVIC M, Attiyeh EF, Ries RE, Goodman EK, et al
    Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Blood. 2017 Apr 14. pii: blood-2017-03-772384. doi: 10.1182/blood-2017-03-772384
    PubMed     Abstract available

  774. GARDNER RA, Finney O, Annesley C, Brakke H, et al
    Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.
    Blood. 2017 Apr 13. pii: blood-2017-02-769208. doi: 10.1182/blood-2017-02-769208
    PubMed     Abstract available

  775. HU S, Qian M, Zhang H, Guo Y, et al
    Whole-genome non-coding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations.
    Blood. 2017 Apr 13. pii: blood-2017-03-771162. doi: 10.1182/blood-2017-03-771162

  776. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
    Blood. 2017;129:2204.

  777. PORCHER C, Chagraoui H, Kristiansen MS
    SCL/TAL1: a multifaceted regulator from blood development to disease.
    Blood. 2017;129:2051-2060.
    PubMed     Abstract available

  778. SOOD R, Kamikubo Y, Liu P
    Role of RUNX1 in hematological malignancies.
    Blood. 2017;129:2070-2082.
    PubMed     Abstract available

  779. AVELLINO R, Delwel R
    Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation.
    Blood. 2017;129:2083-2091.
    PubMed     Abstract available

  780. DE BRUIJN M, Dzierzak E
    Runx transcription factors in the development and function of the definitive hematopoietic system.
    Blood. 2017;129:2061-2069.
    PubMed     Abstract available

  781. UFFMANN M, Rasche M, Zimmermann M, von Neuhoff C, et al
    Therapy reduction in patients with Down Syndrome Myeloid Leukemia: The international ML-DS 2006 trial.
    Blood. 2017 Apr 11. pii: blood-2017-01-765057. doi: 10.1182/blood-2017-01-765057
    PubMed     Abstract available

  782. BELDERBOS ME, Koster T, Ausema B, Jacobs S, et al
    Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
    Blood. 2017 Apr 10. pii: blood-2016-12-758250. doi: 10.1182/blood-2016-12-758250
    PubMed     Abstract available

  783. TAUB JW, Berman JN, Hitzler JK, Sorrell AD, et al
    Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Blood. 2017 Apr 7. pii: blood-2017-01-764324. doi: 10.1182/blood-2017-01-764324.
    PubMed     Abstract available

  784. LANDIER W, Chen Y, Hageman L, Kim H, et al
    Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
    Blood. 2017;129:1919-1926.
    PubMed     Abstract available

  785. DOWSE RT, Ireland RM
    Variant ZBTB16-RARA translocation: morphological changes predict cytogenetic variants of APL.
    Blood. 2017;129:2038.

    March 2017
  786. GO RS, Winters JL, Kay NE
    How I treat autoimmune hemolytic anemia.
    Blood. 2017 Mar 30. pii: blood-2016-11-693689. doi: 10.1182/blood-2016-11-693689
    PubMed     Abstract available

    The classical nature of distinctive CMML monocytes.
    Blood. 2017;129:1745-1746.

  788. FALANGA A
    Predicting APL lethal bleeding in the ATRA era.
    Blood. 2017;129:1739-1740.

  789. TALATI C, Zhang L, Shaheen G, Kuykendall A, et al
    Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
    Blood. 2017;129:1881-1883.

  790. GEYER MB, Hsu M, Devlin SM, Tallman MS, et al
    Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
    Blood. 2017;129:1878-1881.

  791. BACHEGOWDA LS, Saliba RM, Ramlal R, Kongtim P, et al
    Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.
    Blood. 2017 Mar 28. pii: blood-2017-02-766154. doi: 10.1182/blood-2017-02-766154

  792. GARZON R, Savona M, Baz R, Andreeff M, et al
    A phase I clinical trial of single-agent selinexor in acute myeloid leukemia.
    Blood. 2017 Mar 23. pii: blood-2016-11-750158. doi: 10.1182/blood-2016-11-750158
    PubMed     Abstract available

  793. FISCHER K, Al-Sawaf O, Fink AM, Dixon M, et al
    Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Blood. 2017 Mar 21. pii: blood-2017-01-761973. doi: 10.1182/blood-2017-01-761973

  794. CHENG CK, Wang AZ, Wong TH, Wan TS, et al
    FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.
    Blood. 2017 Mar 17. pii: blood-2017-02-767707. doi: 10.1182/blood-2017-02-767707

  795. FRISMANTAS V, Dobay MP, Rinaldi A, Tchinda J, et al
    Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
    Blood. 2017;129:e26-e37.
    PubMed     Abstract available

  796. WONG TN, Link DC
    miR-125b promotes leukemogenesis via VEGFA.
    Blood. 2017;129:1409-1410.

  797. MERTENS D, Stilgenbauer S
    Ibrutinib-resistant CLL: unwanted and unwonted!
    Blood. 2017;129:1407-1409.

  798. SHAFAT MS, Oellerich T, Mohr S, Robinson SD, et al
    Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
    Blood. 2017;129:1320-1332.
    PubMed     Abstract available

    Smart niche usage: release its fat and burn it!
    Blood. 2017;129:1239-1240.

  800. DUNCAVAGE EJ, Uy GL, Petti AA, Miller CA, et al
    Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
    Blood. 2017;129:1397-1401.

  801. GIRARDI T, Vicente C, Cools J, De Keersmaecker K, et al
    The genetics and molecular biology of T-ALL.
    Blood. 2017;129:1113-1123.
    PubMed     Abstract available

  802. HUGHES A, Clarson J, Tang C, Vidovic L, et al
    CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Blood. 2017;129:1166-1176.
    PubMed     Abstract available

  803. KNAPPER S, Russell N, Gilkes A, Hills RK, et al
    A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Blood. 2017;129:1143-1154.
    PubMed     Abstract available

    Immune reconstitution and remission in CML.
    Blood. 2017;129:1064-1065.

  805. STONE RM
    3 + 7 + FLT3 inhibitors: 1 + 1 not equal 2.
    Blood. 2017;129:1061-1062.

  806. ALDOSS I, Song JY
    Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.
    Blood. 2017;129:1231.

  807. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.

  808. LECLERC M, Peffault de Latour R, Michallet M, Blaise D, et al
    Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
    Blood. 2017;129:1227-1230.

    February 2017
  809. AGARWAL P, Zhang B, Ho Y, Cook A, et al
    Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
    Blood. 2017;129:1008-1020.
    PubMed     Abstract available

  810. KORN C, Mendez-Ferrer S
    Myeloid malignancies and the microenvironment.
    Blood. 2017;129:811-822.
    PubMed     Abstract available

    Stopping second-generation TKIs in CML.
    Blood. 2017;129:805-806.

  812. POURABDOLLAH M, Chang H
    Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
    Blood. 2017;129:918.

  813. REITER A, Gotlib J
    Myeloid neoplasms with eosinophilia.
    Blood. 2017;129:704-714.
    PubMed     Abstract available

  814. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Abstract available

  815. ALSULIMAN A, Muftuoglu M, Khoder A, Ahn YO, et al
    A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
    Blood. 2017;129:740-758.
    PubMed     Abstract available

    Introduction to the Review Series on Leukemic Stem Cells.
    Blood. 2017 Feb 3. pii: blood-2017-01-753319. doi: 10.1182/blood-2017-01-753319.

  817. COMOLI P, Basso S, Riva G, Barozzi P, et al
    BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
    Blood. 2017;129:582-586.
    PubMed     Abstract available

  818. PRATZ KW, Levis M
    How I treat FLT3-mutated AML.
    Blood. 2017;129:565-571.
    PubMed     Abstract available

  819. LULLA P, Heslop HE
    Fall of the mutants: T cells targeting BCR-ABL.
    Blood. 2017;129:539-540.

    January 2017
  820. DOHNER H, Estey E, Grimwade D, Amadori S, et al
    Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Blood. 2017;129:424-447.
    PubMed     Abstract available

  821. CHESNAIS V, Arcangeli ML, Delette C, Rousseau A, et al
    Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Blood. 2017;129:484-496.
    PubMed     Abstract available

  822. WARFVINGE R, Geironson Ulfsson L, Sommarin MN, Lang S, et al
    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Blood. 2017 Jan 25. pii: blood-2016-07-728873. doi: 10.1182/blood-2016-07-728873
    PubMed     Abstract available

  823. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Abstract available

  824. ALI ND, Weissmann D
    Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
    Blood. 2017;129:394.

    P53 deletion and NrasG12D cooperate for AML.
    Blood. 2017;129:271-273.

  826. ASKEW D, Pareek TK, Eid S, Ganguly S, et al
    Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
    Blood. 2017;129:246-256.
    PubMed     Abstract available

  827. ABU ZAID M, Wu J, Wu C, Logan BR, et al
    Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
    Blood. 2017;129:162-170.
    PubMed     Abstract available

  828. TARAFDAR A, Hopcroft LE, Gallipoli P, Pellicano F, et al
    CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
    Blood. 2017;129:199-208.
    PubMed     Abstract available

    CML stem cells: evasion for better invasion.
    Blood. 2017;129:141-142.

  830. LEE LY, Hernandez D, Rajkhowa T, Smith SC, et al
    Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
    Blood. 2017;129:257-260.

  831. WALTER MJ
    Antecedent CHIP in CML?
    Blood. 2017;129:3-4.

    December 2016
  832. STRAMUCCI L, Perrotti D
    Twisting IL-1 signaling to kill CML stem cells.
    Blood. 2016;128:2592-2593.

    November 2016
    How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Blood. 2016 Nov 16. pii: blood-2016-08-693507.
    PubMed     Abstract available

  834. CUSAN M, Vegi NM, Mulaw MA, Bamezai S, et al
    Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.
    Blood. 2016 Nov 8. pii: blood-2016-04-706978.
    PubMed     Abstract available

  835. NEFF JL, Chen D
    Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
    Blood. 2016;128:2275.

    August 2016
  836. COOMBS J, Bera E
    B cells mimicking blasts after an allogeneic stem cell transplantation.
    Blood. 2016;128:881.

    February 2016
  837. TEIRA P, Battiwalla M, Ramanathan M, Barrett AJ, et al
    Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis.
    Blood. 2016 Feb 16. pii: blood-2015-11-679639.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.